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ABSTRACT 
 
Predictors and Health Outcomes of Treatment-Resistant Depression  
among Adults with Chronic Non-Cancer Pain Conditions and Major Depressive Disorder 
 
Drishti Shah 
Understanding major depressive disorder (MDD) as a comorbidity in patients with chronic non-
cancer pain conditions (CNPC) is of importance because of the high prevalence and well 
documented bi-directional relationship between MDD and pain. Furthermore, presence of CNPC 
among adults with MDD often reduces benefits of antidepressant therapy, thereby increasing the 
possibility of treatment resistance. Treatment-resistant depression (TRD) commonly defined as 
insufficient response to multiple antidepressant trials, often worsens depression and pain 
symptoms and can amplify the clinical and economic burden among adults with CNPC and 
MDD. Additionally, long-term opioid therapy (LTOT) may be prescribed at a higher rate to 
adults with TRD to treat an undifferentiated state of physical and mental pain, despite lack of 
evidence on LTOT use in this patient population.  Existing literature on TRD has focused on all 
adults with MDD. Owing to the lack of research on TRD among adults with CNPC and MDD, 
we conducted this study to fill a critical knowledge gap. This dissertation pursued three related 
aims: 1) identify leading predictors of TRD; 2) estimate the direct economic burden associated 
with TRD and identify factors that contribute to the excess cost burden of TRD; and 3) examine 
the trajectory of LTOT use in adults with CNPC and newly diagnosed MDD and how TRD can 
alter this trajectory. The study used a retrospective, longitudinal, cohort design, using multiple 
years (2007-2017) of the de-identified, geographically diverse data on commercially insured 
adults obtained from the 10% random sample of Optum® Clinformatics® Data Mart. TRD was 
identified using a comprehensive claims-based algorithm. Among adults (>18 years) with CNPC 
and newly diagnosed MDD who were treated with antidepressants (N=23,645), approximately 
one in nine adults transitioned to TRD within a year of MDD diagnosis. First, we identified the 
use of mental health specialist visits, polypharmacy, psychotherapy use, anxiety, and age to be 
the five leading predictors of TRD using random forest, a machine learning method and cross-
validated logistic regression. In the second aim, we observed that patients with TRD had 
significantly higher direct all-cause ($21,015TRD vs. $14,712No TRD) and MDD-related costs 
($1,201TRD vs. $471No TRD), and healthcare resource utilization (e.g. IRR for inpatient visits = 
1.30. 95% CI = 1.14-1.47; P<0.001) as compared to those without TRD. Majority of excess total 
healthcare costs among adults with TRD were driven by differences in rates of polypharmacy 
between the TRD and non-TRD groups. Lastly, findings from the third aim indicated that adults 
with TRD were more likely to receive LTOT [AOR: 1.54, 95% CI: 1.68-2.04), although LTOT 
use among TRD group declined over the three-year observation period, at a higher rate than 
those without TRD (β= -.033, SE=0.012).  In summary, these findings underscore the need for 
effective, evidence-based strategies to manage depression and pain among adults with TRD and 
CNPC. In addition, the current study identified modifiable factors that warrant further 
investigation and may serve as potential targets for clinical and policy interventions to reduce the 
risk of TRD and off-set the excess costs associated with TRD. Furthermore, high rates of LTOT 
use among adults with TRD suggest that clinicians need to closely monitor the risks of using 
LTOT in this subgroup. 
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CHAPTER 1  
1 Introduction 
1.1 Background and Significance 
Epidemiology of Major Depressive Disorder 
Major Depressive Disorder (MDD) is the leading cause of disability worldwide, and is a 
major contributor to the burden of suicide.1 MDD is highly prevalent and affects approximately 
35 million adults in the United States (US).2,3 Among adults in US, MDD accounts for nearly 3.7 
percent of all disability-adjusted life years (DALYs) and 8.3 percent of all years lived with 
disability (YLDS).4 MDD disproportionately affects women; women are 70% more likely to 
experience MDD during their lifetime than men. As per the National Comorbidity Study, the 
lifetime prevalence of MDD in the US was estimated to be 21.3% in women and 12.7% in men.5 
It has been reported that MDD is significantly associated with increased risk of other psychiatric 
disorders, notably anxiety disorders, substance use disorders and other chronic conditions such as 
chronic non-cancer pain conditions (CNPC).2, 6,7 MDD also plays a significant role in worsening 
functional status, with the greatest impairment in the social and cognitive domains.2 
Burden of MDD 
  MDD is associated with significant clinical, humanistic, and economic burden.1,8 It is 
projected to cause the greatest illness burden in high-income countries by 2030.9 In 2015, the 
incremental economic burden of MDD in the US was estimated to be as high as $210.5 billion, 
with $98.9 billion spent on direct healthcare costs.8 Co-existence of MDD and other chronic 
conditions has been reported to be the main driver of this high economic burden associated with 
MDD.8 For example, MDD is associated with 50% to 100% higher medical costs among patients 
with co-existing chronic conditions even after risk adjustments.10 Among commonly co-
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occurring chronic conditions with MDD, chronic non-cancer pain conditions (CNPC) is of 
particular interest because of the high prevalence and well documented bi-directional 
relationship between MDD and pain.7,11 
MDD among Adults with Chronic Non-cancer Pain Conditions   
Of all the chronic conditions that can co-exist or develop in MDD patients, commonly 
occurring CNPC including, back/neck pain, headache/migraine, and neuropathic pain conditions 
deserve special attention because of the special pathophysiology between MDD and CNPC. 
Link between MDD and CNPC 
 MDD and painful symptoms, commonly experienced by adults with CNPC often co-
occur together. 7,12 MDD and its treatment can be affected by pain, which is also considered as a 
somatic symptom of depression.13 A growing body of literature has documented the bi-
directional relationship between chronic pain and MDD. As pain and MDD are inextricably 
linked in terms of the shared biological pathways and neurotransmitters, they often respond to 
similar treatments, and exacerbate one another. Some researchers have labeled this relationship 
as depression-pain syndrome.14,15 It has been suggested that one of the important causes for 
chronic pain leading to depression and vice versa appears to be the common neuroplasticity 
changes shared by pain and depression such as changes in monoamine neurotransmitters, brain-
derived neurotrophic factor, inflammatory factors, and glutamate functions.16 
Prevalent MDD among Adults with CNPC 
  Given that pain is often experienced by adults with CNPC, several studies have examined 
the prevalence of MDD in patients with CNPC. A narrative review on MDD and pain 
summarized the prevalence of MDD in adults with CNPC and reported that the estimated 
prevalence of MDD in patients with CNPC can be as high as 85%. 7 However, depending on the 
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type of condition and setting,7 MDD prevalence can range from 38% in psychiatric clinics, 52% 
in pain clinics, 56% in orthopedic or rheumatology clinics, and to 85% in dental clinics.7   
Treatment-Resistant Depression among Adults with MDD 
 A significant proportion of the economic and clinical burden of MDD is 
disproportionately accounted by individuals who do not achieve recovery from the illness. 
Consensus exists that a majority of individuals (nearly 50%) do not achieve complete remission 
with index antidepressant therapy. The designation -“treatment-resistant depression (TRD)” is 
primarily used to describe patients who do not respond to more than two adequate trials of 
antidepressants.17-20 The STAR*D trial, the largest and longest study ever conducted to evaluate 
the effectiveness of depression treatment reported that even after undergoing four sequential 
antidepressant trials, 30% of patients did not achieve remission.21 Due to the variations in TRD 
definitions in studies using administrative claims or similar datasets, the prevalence of TRD has 
ranged from 6%22 to 30%.23 
High risk of TRD among Adults with CNPC and MDD 
 CNPC may contribute to TRD among adults with MDD. Biar et al investigated the 
presence of pain conditions on treatment response to depression in primary care.11  They 
concluded that the presence of baseline CNPC among adults with MDD reduces the benefits of 
antidepressant therapy at 12 weeks, suggesting treatment resistance.11  Indirect evidence of the 
relationship between CNPC and TRD has been reported.  A Canadian Study by Rizvi et al. and a 
US study by Kubitz et al. reported that the prevalence of CNPC such as joint pain, muscle pain, 
headache/migraine, and back pain was two times higher among patients with TRD as compared 
to those without TRD.22,24  It is plausible that adults with CNPC may be at higher risk of having 
TRD, because pain experienced by those with CNPC may reduce the efficacy of antidepressant 
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therapy. 11 However, to date, no study has systematically examined the risk of TRD among 
adults with CNPC and MDD, suggesting a significant need for studies on TRD among adults 
with CNPC. In this context, the first critical step in filling this knowledge gap is an examination 
of risk factors that influence the transition from MDD to TRD among adults with CNPC. 
Risk Factors for TRD among Adults with CNPC and MDD 
 TRD can be influenced by biological, health- and treatment- related factors.  In studies 
not specific to CNPC, it has been reported that women (71%), non-Hispanic whites (89%), adults 
with comorbid conditions (for example, CNPC, cardiovascular diseases, hypertension, and other 
psychiatric conditions), obesity, highly activated inflammatory system, and patients who are 
hospitalized were more likely to experience TRD compared to those without these risk factors. 
20,22,24,25 Recent studies conducted using predictive models to identify risk factors of TRD using 
data obtained through the Group for the Study of Resistant Depression (GSRD),  across 
participating centers in Europe concluded that depression severity, age, time span between first 
and last depressive episodes, suicidal risk, body mass index, number of past depressive episodes, 
and lifetime duration of hospitalizations were important predictors of TRD.26-28 It has to be noted 
that these studies included prevalent cases of MDD and therefore, the identified factors may not 
be plausible risk factors for TRD among patients with newly diagnosed MDD. Another study 
that sought to find risk factors of TRD among patients with newly diagnosed MDD reported that 
patients with TRD were more likely to be younger, have a history of substance use disorders, 
psychiatric conditions, insomnia, and pain as compared to non-TRD patients. 29 However, to 
date, no study has identified risk factors of TRD among adults with CNPC and newly diagnosed 
MDD. 
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 As the current study focused on adults with CNPC and MDD, in addition to the above 
factors, association of treatment factors with TRD, such as pain therapy commonly used for 
CNPC needs to be investigated. It has been reported that effective pain treatment can relieve 
depressive symptoms 36,37 and may therefore reduce the risk of TRD. On the other hand, type of 
pain treatment can positively or negatively impact TRD. For example, opioid use may increase 
the risk of TRD. A retrospective study on the dose and duration of opioid therapy on TRD 
among Veterans reported that longer duration of opioid treatment increased the risk of 
transitioning from MDD to TRD.30  Pain treatment with nonsteroidal anti-inflammatory drugs 
(NSAIDs) may improve depression outcomes among adults with specific CNPC such as 
osteoarthritis.31,32 As the long term use of opioids in patients with CNPC is not effective, 33,34 
there is critical a need to assess the association of other pain therapies such as the use of 
NSAIDs, and other non-pharmacological pain therapies such as psychotherapy with TRD. Since 
psychotherapies such as cognitive behavioral therapies are effective for treating both MDD and 
chronic pain, they may reduce the risk of TRD.35 
The current study also included factors that have not been examined in other studies such 
as polypharmacy. It has been documented that the concurrent use of 3 or more medications with 
depression as an adverse event may increase the risk of having concurrent MDD.36 Additionally, 
certain commonly used medications (e.g. benzodiazepines, corticosteroids, and beta-blockers, 
and certain muscle relaxants) have higher rates of drug-drug interactions with antidepressants 
and dilute plasma concentration of antidepressants, which may lead to poor clinical response and 
TRD.37 Therefore, polypharmacy as a predictor of TRD needs to be investigated. 
Early identification of leading predictors of TRD in real-world clinical settings with 
robust statistical and machine leaning methods can inform targeted treatment approaches. As 
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these predictive models require a large of number of observations, population-based claims data 
can be ideal.38,39  This leads to the rationale for Aim 1, which examined the risk factors of 
transitioning from MDD to TRD among adults with CNPC and newly diagnosed MDD. 
Role of TRD in Amplifying Burden of MDD 
A review on the disease burden of TRD highlighted that the number of medication-
related adverse events were higher and the quality of life scores were 26 points lower for adults 
with TRD when compared to those adults with MDD who experienced remission.20 Additionally, 
adults with MDD also incur a higher economic burden due to TRD. Those with TRD have an 
excess annual direct healthcare cost of $5,461 per patient and an additional $4,048 per patient in 
productivity losses. Extrapolating these costs to national level yielded an estimated $29-$46 
billion due to TRD (depending on the prevalence estimates of 12 and 20 percent respectively), 
thereby pushing up the total societal costs of MDD to as high as $106-$118 billion.20 The burden 
of TRD is on par with or even higher than other medical conditions such as cancer and diabetes, 
yet MDD ranks 15th among conditions that receive funding from the National Institutes of 
Health,40 thereby underscoring the need for more research on TRD.  
Economic Burden of TRD 
Nearly one-third of the excess cost of MDD has been attributed to TRD.20  Among 
working-age adults with MDD, several studies have quantified the direct healthcare utilization 
and costs associated with TRD. 22,23,25,30,41-45 Although the reported incremental economic burden 
of TRD varied depending on the definition of TRD and type of study setting; on an average, 
working age adults with TRD had two times higher direct healthcare costs as compared to those 
without TRD. 23,25,41,42 A recent study that estimated the cost burden of TRD reported that adults 
with TRD incurred $6,709 and $9,917 higher per patient per year costs as compared to non-TRD 
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adults with MDD and non-MDD patients.46 Furthermore, those with TRD  also had significantly 
higher odds of using inpatient, outpatient and ER services.23,25,22 However, none of these existing 
studies have estimated the economic burden of TRD among adults with CNPC. A population 
based study that did not focus on TRD concluded that the presence of concomitant pain 
conditions in patients with MDD initiated 20% higher visits to medical providers than those with 
MDD but no pain conditions.47 Presence of TRD can further amplify this burden.  
Understanding the relationship between TRD and healthcare costs and utilization among 
a specific subgroup of patients with CNPC can provide meaningful information to payers and 
policy makers on how patients’ MDD and pain-related complexity can affect healthcare resource 
use. Given limited healthcare resources, healthcare costs have always been an essential measure 
of health outcomes in the US. In response to the rising healthcare costs, the Institute of Health 
Improvement developed the “Triple Aim” which requires identification of high-cost, high-need 
patients. 48 Therefore, such cost of illness studies are important not only to provide benchmark 
for evaluation of alternative demands on scarce health care resources, but also help in translating 
the burden of illness into dollar terms, the universal language for decision making.49 As there are 
no cost estimates on TRD among adults with CNPC and MDD, estimates obtained from the 
current study can be used as input parameters in future cost-effectiveness studies. 
 Furthermore, as highlighted above, TRD can be influenced by many factors. 20,27,29,50  
Identification of key contributors of the incremental TRD burden using advanced decomposition 
methods can assist policy makers in assessing if the limited healthcare resources are being 
inequitably used and can aid payers in identifying major cost drivers. This leads to the rationale 
for Aim 2, which estimated the incremental economic burden (direct healthcare utilization and 
costs) associated with TRD among adults with CNPC and newly diagnosed MDD. In addition, a 
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post-regression decomposition approach was adopted to explain patient level factors that may 
contribute to the difference in total healthcare costs between adults with and without TRD. 
Role of TRD in the trajectory of pain treatment with opioids among adults with CNPC
 As stated before, pain is a hallmark symptom of CNPC and is also a somatic symptom of 
MDD.7,11 It difficult to manage pain among patients with CNPC and MDD for several reasons: 
1) patients with co-existing CNPC and MDD report higher pain scores as compared to those with 
CNPC but no MDD;51 2) increased difficulty in managing chronic pain and MDD may come 
with patients that also have substance use disorders. For example, it has been reported that 
patients with MDD are 1.8-2.4 times likely to misuse opioid medications;53) patients with MDD 
and pain report higher impairment in functional capacity; 4) depression severity increases when 
pain is more diffuse, as indicated by multisite pain, often experienced by patients with CNPC.52 
 As adults with co-existing CNPC and MDD may experience pain at higher intensity 
which may not be responsive to first line pain therapies such as NSAIDs, opioids may be 
prescribed for longer duration. There has been a growing need to examine the risks of long-term 
opioid therapy (LTOT) among patients with CNPC due to the concern that the safety and 
effectiveness of LTOT in CNPC remains unproven.53,54 Further, no treatment guidelines 
recommend LTOT for patients with CNPC who also have MDD.55 Yet patients with CNPC and 
MDD continue to receive LTOT in real-world settings. 55 As MDD often makes chronic pain 
worse among adults with CNPC, 11patients with MDD and chronic pain may often preferentially 
seek relief for their pain, which may be less stigmatized. Health care providers may be obligated 
to prescribe medications such as opioids to treat the undifferentiated state of physical and mental 
pain in these patients. In fact, patients with MDD in real-world are more likely to receive LTOT 
than those without MDD diagnoses.56 
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As patients with TRD experience worse depression symptoms and physical symptoms 
such as pain as compared to those without TRD,26 LTOT may be prescribed at a higher rate 
among patients with TRD. TRD may increase the use of  LTOT55 as the neural patterns of 
activation that are associated with depression are also associated with pain, and LTOT may be 
prescribed to treat the complex combination of both pain and TRD.55,57 In addition, historically 
opioids have been used to treat psychological distress caused by mental health conditions.5,58  
LTOT  in patients with TRD may further exacerbate the risk of opioid misuse leading to 
detrimental consequences such as death due to overdose, intentional harm, and suicide.1,5 On the 
other hand, clinicians may be more cautious in prescribing LTOT to MDD patients who develop 
TRD. This is because this group of patients may be deemed to be a high- risk group as both 
LTOT and TRD are independently associated with increased risk of substance use disorders and 
adverse health outcomes. 30, 3220,22 While, there is evidence that patients with MDD and pain are 
more likely to receive LTOT,56,59,60 and LTOT may increase the risk of TRD,30  to date, no study 
has examined the trajectory of LTOT use among patients with CNPC and MDD and how TRD 
may alter this trajectory. 
The central question in prescribing LTOT for CNPC and TRD is how to best balance the 
risk of opioid abuse and dependence. The first critical step in answering this question is an 
understanding of the pattern of LTOT prescription among adults with CNPC and MDD and the 
association of TRD with the trajectory of LTOT use. Robust evidence on the pattern of LTOT 
use among adults with CNPC and MDD and any efforts to understand the risk factors of LTOT 
are useful in the broader context of battling the current opioid epidemic. Findings from the 
current study can inform clinical practice, payers, and policy makers in their surveillance efforts 
of controlling long- term opioid use and misuse. Therefore, a study examining the trajectory of 
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LTOT in adults with CNPC and newly diagnosed MDD and the association of TRD with LTOT is 
needed, thereby justifying the rationale for aim 3 of the current study.  
1.2 Innovation 
a) Comprehensive evaluation of risk factors associated with TRD among adults with 
CNPC and newly diagnosed MDD: This is the first study to conduct comprehensive 
analyses of biological, health- and treatment- related factors associated with TRD among 
adults with CNPC and newly diagnosed MDD using a large, geographically diverse 
dataset of commercially insured adults. 
b) Use of a comprehensive and nuanced claims-based algorithm to identify adults with 
TRD in a unique population of adults with CNPC and MDD:  The current study 
applied a comprehensive claims-based algorithm, developed using the Massachusetts 
General Hospital (MGH) clinical staging method. 23,61 This algorithm has been previously 
used by Gibson et al. to identify adults with TRD and estimate the cost burden of TRD 
among adults with MDD. 23 Several existing studies have defined TRD based on a single 
criterion or a combination of criteria such as number of antidepressant switches, number 
of titrations, and concomitant administration of antidepressants, mood stabilizers or 
atypical antipsychotics. 22,29,30,46 Unlike approaches based on a single criterion, the MGH 
scoring based approach used in this study is comprehensive as it includes the four main 
strategies to overcome lack of response i.e. optimization, switching, combination or 
augmentation. 62  Further this approach can be easily translated to prescription data 
available in pharmacy claims.23 To date, no study has used this approach to identify TRD 
among adults with CNPC and MDD. 
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c) Novel risk factors of TRD: As the current study specifically focuses on adults with 
MDD and CNPC, it used several novel risk factors of TRD such as polypharmacy, type 
of pain treatment, and number of CNPC conditions. Association of these risk factors with 
TRD has not been established in previous studies on adults with MDD.    
d) Fill a significant knowledge gap in literature: Given that no studies have examined 
TRD among adults with co-existing CNPC and MDD, the proposed study will fill an 
important knowledge gap in literature by identifying leading predictors of TRD, 
quantifying excess economic burden associated with TRD and examining the association 
between TRD and LTOT. 
e) Use of advanced predictive modeling to identify leading predictors of TRD using 
routinely collected insurance claims data: use of predictive modeling to identify 
patients who are at risk for transitioning from MDD to TRD among individuals with 
CNPC will help in understanding modifiable factors which can guide clinicians in 
intervening early to reduce the risk of TRD. Additionally, targeted interventions can be 
designed for this sub-group of patients to improve clinical outcomes and reduce future 
medical costs and, healthcare utilization. 
f) Application of econometric techniques to identify the difference in characteristics 
between patients with and without TRD that explain the excess total healthcare 
expenditures associated with TRD: This is the first study to examine the contribution of 
various patient level differences between adults with TRD and without TRD to the 
observed gap in total healthcare costs between the two groups from a population based 
perspective. 
1.3 Specific Aims 
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AIM 1:  Identify leading predictors of transitioning from MDD to TRD among adults with 
CNPC and newly diagnosed MDD in a real-world setting using a machine learning 
approach. 
Hypothesis: In adjusted models, that include all the predictors, presence of chronic 
conditions, anxiety disorders, sleep disorders, substance- use disorders, age, and 
polypharmacy will be leading predictors of TRD among adults with CNPC and newly 
diagnosed MDD. 
AIM 2:  Estimate the direct economic burden (direct healthcare costs and utilization) of 
TRD and its contributory factors among adults with CNPC and newly diagnosed MDD 
using post-regression decomposition techniques. 
Hypothesis: Adults with TRD will have significantly higher direct healthcare costs and 
utilization as compared to adults without TRD; the majority of excess costs due to TRD 
will be explained by differences in the type of CNPC, presence of obesity, sleep disorders, 
and other chronic conditions between the two groups. 
AIM 3: Examine the trajectory of LTOT over a 3-year period in adults with CNCP and the 
association of TRD with LTOT among adults with CNPC and newly diagnosed MDD.  
Hypothesis:The use of LTOT will decline over the 3-year study period and adults with TRD 
will be more likely to use LTOT as compared to adults without TRD. 
1.4 Approach 
Conceptual Framework 
 Aim 1: Extensive literature review and a conceptual framework adapted from the modified 
determinants of health outcomes and chronic disease model was used to identify the plausible 
risk factors of TRD.63 This framework was originally proposed by Wilkinson and Marmot.63  
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The model suggests that incidence of a disease (in this case TRD) can be affected by several 
dimensions. These dimensions include: 1) community resources (e.g. geographical region), 2) 
access to care factors (e.g. Medicare enrollment, type of plan and co-pay), 3) treatment- related 
factors (e.g. pain treatment such as opioid use, NSAID use, use of psychotherapy, type of 
provider such as primary care provider, specialist, mental health specialist, polypharmacy, class 
of index antidepressant medication, and inpatient status), 4) biological risk factors (e.g. age, sex), 
and 5) health-related factors which comprises of two sub-domains, mainly chronic health 
conditions (e.g. CVD, hypertension, diabetes, asthma, COPD, anxiety disorders, dementia, sleep 
disorder, osteoporosis, and type of CNPC), and lifestyle factors (e.g. substance use, tobacco use, 
alcohol use and obesity).  
 
Figure 1.1: Adapted determinants of health outcomes and chronic disease model 
Aim 2: The conceptual framework for Aim 2 was based on the adapted Andersen’s 
Behavioral Model of Health Services Use,64 which posits that healthcare utilization of an 
individual is a function of multiple factors. These factors can be grouped into four domains, 
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including 1) predisposing factors that represent the individual characteristics predictive of using 
healthcare services (e.g., age, sex); 2) enabling factors that may enable access to healthcare 
services (e.g. Medicare advantage enrollment, type of insurance plan); 3) need factors that define 
an individual’s health status (e.g. chronic conditions, obesity, sleep disorders,  tobacco use 
disorder, and substance use disorder, polypharmacy, benzodiazepine use, and use of pain 
medication such as opioids and NSAIDs); and 4) environmental factors that may influence an 
individual’s healthcare utilization (e.g. geographical region).  
 Aim 3: To guide the process of variable selection for aim 3 of the current study, the 
expanded Symptom Management Model was used.65,66 The generic symptom management 
model has three dimensions: symptom experience, management strategies and outcomes. The 
dimension of symptom experience can be described as perception of symptom as well as a 
response to a symptom. As per the proposed framework, presence of TRD, which is mainly non-
response to depression treatment trials, was considered as a symptom which can influence the 
outcome of LTOT. As per the model, the above dimensions are influenced by the following three 
domains: (1) the personal domain, which comprised of demographic factors (e.g. age, sex, 
insurance plan type, Medicare advantage enrollment), psychological factors (e.g. presence of 
anxiety and other mental health comorbidities); (2) the health and illness domain (e.g. chronic 
physical conditions, obesity, sleep disorders, substance use disorders, polypharmacy, 
benzodiazepine use, and use of pain medication such as NSAIDs); (3) the environmental domain 
(e.g. geographical region, index year of MDD diagnosis). 
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Figure 1.2 Expanded Symptom Management Model 
Data Sources 
To accomplish the study objectives, we used the 10% sample of de-identified health 
insurance claims data from Optum Clinformatics ® DataMart (Optum Clinformatics®, Eden 
Prairie, MN, USA) for the period of 1st January 2007 through 30th June 2017. This nationally 
representative, geographically diverse database contains a combination of inpatient, outpatient 
and pharmacy claims for individuals enrolled in the commercial insurance plans and Medicare 
Advantage plan of a large U.S. health insurance company. The data also contains information on 
lab results, certain demographic characteristics (e.g year of birth, sex, residential state) and plan 
type (e.g. health maintenance organization, preferred provider organization, point of service, fee-
for-service )that are routinely collected during health insurance enrollment.67 The data contains a 
10% random sample of information on 47 million individuals, approximately 80% of whom 
purchased insurance from their employers. 
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CHAPTER 2  
2 Predictors of Treatment-Resistant Depression among Adults with Chronic Non-Cancer 
Pain Conditions and Major Depressive Disorder: A Machine Learning Approach 
2.1 Abstract 
Objective: Presence of chronic non-cancer pain conditions (CNPC) among adults with major 
depressive disorder (MDD) often reduces benefits of antidepressant therapy, thereby increasing 
the possibility of treatment resistance. This study sought to identify leading predictors of 
treatment-resistant depression (TRD) among adults with newly diagnosed MDD and CNPC 
using machine learning approaches. 
Methods: This retrospective cohort study included adults (>18 years) with newly diagnosed 
MDD and CNPC from a de-identified 10% random sample of Optum® Clinformatics® Data 
Mart (2007-2017). TRD was identified using the Massachusetts General Hospital clinical staging 
algorithm for claims data. Random forest (RF), a machine learning method, was used to identify 
leading predictors of TRD. Initial model development included 42 known and/or probable risk 
factors for TRD. The final refined model included 20 risk factors. To facilitate comparison with 
published studies, results from logistic regression are presented. 
Results: Included in the sample were 23,645 patients (73% female mean age: 55 years; 78% 
with >2 CNPC, and 91% with joint pain/arthritis). Overall, 11.4% (N = 2,684) transitioned from 
newly diagnosed MDD to TRD.  The five leading predictors of TRD were: mental health 
specialist visits, polypharmacy (>5 medications), psychotherapy use, anxiety, and age. Cross-
validated logistic regression model indicated that those with TRD were younger, more likely to 
have anxiety, mental health specialist visits, polypharmacy, and psychotherapy use with AORs 
ranging from 1.9-1.3 (all Ps < 0.01). 
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Conclusion: Machine learning identified several modifiable factors that warrant further 
investigation and may serve as potential targets for clinical intervention to improve treatment 
outcomes in those with TRD.   
2.2 Introduction 
Major Depressive Disorder (MDD) affects approximately 350 million adults worldwide 
and 35 million adults in the United States (US).3,68 Major Depressive Disorder is the leading 
cause of disability and a major contributor to the overall global illness burden.1,69 Despite the 
efficacy of various antidepressant medications in improving depression symptoms, many adults 
with MDD in real-world settings do not respond to repeated trials of antidepressants. 70,71 
Therefore, a significant proportion of the burden of MDD can be attributed to treatment resistant 
depression (TRD).20 Although there is lack of consensus on the definition of treatment resistant 
depression (TRD), the designation -“TRD” is primarily used to describe patients who do not 
respond to at least two adequate trials of antidepressants.17-20,72 Due to the variations in study 
population, follow-up time period, datasets used, and measures used to define TRD, the 
prevalence of TRD has ranged from 6%22 to 30%21 in published studies. For example, the 
Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial, the largest and longest 
study ever conducted to evaluate the effectiveness of depression treatment reported that even 
after undergoing four sequential antidepressant trials, 30% of patients did not achieve 
remission.21,72 
Published studies have suggested that some subgroups of patients with MDD may be 
more likely to have TRD.20,22,24,29 These studies have consistently reported higher prevalence of 
TRD among adults with chronic non-cancer pain conditions (CNPC). 20,22,24,29 It is plausible that 
individuals with CNPC may be more likely to transition into TRD because MDD and its 
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treatment can be affected by pain, often considered as a somatic symptom of depression.13 A 
growing body of literature has documented the bi-directional relationship between pain and 
MDD. As pain and MDD are inextricably linked in terms of the shared biological pathways and 
neurotransmitters, they often respond to similar treatments, and may also exacerbate one another. 
Some researchers have labeled this relationship as depression–pain syndrome.14,15 A narrative 
review on MDD and pain estimated that the prevalence of MDD in patients with CNPC can be as 
high as 85% and can range from 32%-85% depending on the type of condition and setting.7 A 
study by Biar et al. concluded that presence of baseline CNPC among adults with MDD reduces 
the benefits of antidepressant therapy at 12 weeks, suggesting treatment resistance.11  Indirect 
evidence of the relationship between CNPC and TRD has been reported. A Canadian Study by 
Rizvi et al. and a US study by Kubitz et al. reported that the prevalence of CNPC such as joint 
pain, muscle pain, headache/migraine, and back pain was two times higher among patients with 
TRD, as compared to those without TRD.22,24   
The transition from MDD to TRD can be influenced by many factors. In studies not 
specific to CNPC, severity of depression, response to first antidepressant treatment, number of 
past depressive episodes, obesity, highly activated inflammatory system, inpatient status, 
presence of anxiety, insomnia, pain, and other social factors have been identified as risk factors 
of TRD20,22, 26,28,29,50,73,74 While there is literature on risk factors of  TRD among general 
population with MDD, among a sub-group of adults with CNPC and MDD, additional probable 
risk factors such as pain therapy commonly used for CNPC needs to be examined. Certain 
commonly used analgesic medications and other medications such as benzodiazepines, 
corticosteroids, and beta-blockers may have mood related adverse effect or have higher rates of 
drug-drug interactions with antidepressants which can lead to safety concerns, poor clinical 
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response, and may increase the risk of TRD.36,37 As adults with CNPC are more likely to have 
polypharmacy, the potential for drug-drug interactions may be greater with severe health 
consequences.75,76  Therefore, polypharmacy as a predictor of TRD needs to be investigated. 
To our knowledge, to date, no study has systematically examined the risk of TRD among 
adults with CNPC and MDD. In this context, the first critical step in filling this knowledge gap is 
an examination of risk factors that can influence the transition from MDD to TRD among adults 
with CNPC. When a patient is newly diagnosed with MDD, the presence of characteristics that 
could increase the risk of TRD may alert healthcare providers to monitor the patients more 
closely. Identification of leading predictors of TRD in real-world clinical settings with robust 
statistical and machine leaning methods can help clinicians understand treatment response and 
inform targeted individualized treatment approaches. Furthermore, non-parametric machine 
learning methods can improve predictive accuracy by reducing over fitting even in the presence 
of complex interactions, as compared to standard parametric approaches. 77As these predictive 
models require a large of number of observations and predictors, population-based claims data 
can be ideal.38,39  Therefore, the primary objective of the study is to identify leading predictors of 
transitioning from MDD to TRD among adults with CNPC and newly diagnosed MDD in a real-
world setting using a machine learning approach. 
2.3 Methods 
Study design and Data Source 
We used a retrospective cohort study design. The cohort included all adults (age > 18 
years) with newly diagnosed MDD and CNPC. We used de-identified patient data with medical 
and pharmacy claims as well as enrollment information from the Optum® Clinformatics® Data 
Mart67 for the period January 2007 to June 2017.  For this study, we used a 10% random sample 
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extracted from a nationally representative, geographically diverse database of 47 million 
individuals. The data comprised adults who were insured in a commercial plan as well as 
Medicare Advantage plans. 67 
Newly diagnosed MDD was identified between January 2008 and June 2016 using a 
validated and published algorithm.78,79  The first observed MDD diagnosis during a calendar year 
was identified using ICD-9-CM (International Classification of Diseases, Ninth Revision, 
Clinical Modification) or ICD-10 CM (International Classification of Diseases, Tenth Revision, 
Clinical Modification) diagnosis codes as appropriate (See in Appendix 7.1). A 180-day look-
back period was used to ensure that the individuals did not have any MDD claims or 
antidepressant prescriptions.  
 The date of newly diagnosed MDD (index date) was used to create the baseline period (12 
months before the index date) and the follow-up period (12 months after the index date). The 
baseline period was used to identify CNPC and other predictors (see Measures section). The 
follow-up period was used to identify TRD and MDD treatment-related factors during the acute 
phase of treatment, before TRD identification (first 90 days after MDD diagnosis) (Appendix 
7.2). 
Analytical Sample 
 
The analytical sample consisted of adults with CNPC identified in the 12 months before 
MDD diagnosis. CNPC was identified using an extensive list of 1000 conditions for which pain 
was severe enough to call them as CNPC.80-82 The diagnoses were further collapsed into four 
major pain categories: arthritis/joint pain, back/neck pain, headache/migraine, and neuropathic 
pain/other chronic pain conditions. 80-82 We required at least two healthcare encounters in an 
inpatient or outpatient setting for identification of adults with CNPC. The ICD 9/10 diagnosis 
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codes used to identify CNPC are provided in the Appendix 7.2. Other inclusion/exclusion criteria 
were: at least one antidepressant prescription after MDD diagnosis; continuous enrollment 
during the baseline and follow-up period (24 months); no cancer diagnosis at any time during the 
study period; and consistent with prior studies, individuals having any diagnosis of 
schizophrenia, schizoaffective disorder, other psychosis, manic depression or bipolar disorders 
were excluded. 22,23 The final analytical sample consisted of 23,645 adults with CNPC and newly 
diagnosed MDD (See Figure 1 for number of individuals eliminated at each step of 
inclusion/exclusion criteria). 
Outcome 
Treatment-Resistant Depression 
 The primary outcome was the transition to TRD within a year after the index date. 
Identification of TRD using insurance claims data is challenging for several reasons: 1) there is 
no universally accepted definition of TRD; 2) lack of information on depression symptoms and 
severity; and 3) availability of prescription rather than actual use of antidepressants. 42 Therefore, 
studies using administrative claims have used several different algorithms to define TRD. These 
have typically included single criterion such as number of antidepressant switches, number of 
titrations, concomitant administration of antidepressants, mood stabilizers or atypical 
antipsychotics, or a scoring method based on all of the above. 22,23,41,42 Additionally, use of 
electroconvulsive therapy is also considered as a marker of TRD because ECT is often used as a 
late-stage treatment for TRD.41 
 We applied the Massachusetts General Hospital (MGH) clinical staging method to insurance 
claims to identify individuals with TRD.  This algorithm has been previously used to predict the 
cost burden of TRD 23,61 We selected this algorithm because it includes the four main strategies 
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to overcome lack of therapeutic response, i.e. optimization, switching, combination or 
augmentation and can be easily translated to prescription data available in pharmacy claims.62 
Using this approach, we assigned 1 point for each adequate antidepressant trial (i.e., two or more 
fills of the same antidepressant), half a point for each of the following optimization strategy: 
extended duration defined as > 3 fills of the same antidepressant, an upward titration in dose, and 
augmentation with atypical antipsychotic/mood stabilizer. An overall score exceeding three was 
used as a threshold to establish TRD and those with a score exceeding three were classified as 
having TRD.23An MGH score of three is the equivalent to two distinct antidepressant trials with 
one optimization strategy such as augmentation.29 Any additional optimization or augmentation 
strategy would meet the threshold for TRD.83 Those using electroconvulsive therapy (ECT) were 
considered to have TRD. 
Statistical and Prediction Analyses 
Unadjusted associations between predictors and TRD were examined using chi-square 
tests for categorical variables and t-tests for continuous varibles. Multivariable logistic regression 
(LR), a method familiar to many researchers is a standard technique for analysis of binary 
outcomes in medicine and social science, where the focus is not only on prediction, but also on 
explaining the association between variables.84 Logistic regression, a standard parametric method 
makes several assumptions about the data.84 Recently, algorithmic or machine learning methods 
that do not have any strong parametric assumptions have gained popularity because they can be 
used on large complex datasets and can provide better accuracy.85 A common theme among all 
the algorithmic models is validation and testing of models using random bootstrap samples. 
Although many types of machine learning methods are available for binary outcomes such as the 
presence or absence of TRD, random forest (RF) is a particulary attractive alternative because of 
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its many advantages such as high predictive accuracy, reduction in overfitting, and  identification 
of most useful set of features. RF is based on decision trees, which represent the relationships of 
variables in the dataset. Each decision tree models hierarchical relationships between predictors 
and outcomes by maximing the amount of information gain.  
We used the caret and randomForest package for R software for building the machine 
learning predictive models using LR and RF.86 To create and train the models the data was 
randomly split into a 70% training sample (N=16,570) and was internally validated using a 30% 
test sample (N=7,075). The training sample was used for model refinement, learning, and to 
determine the model coefficients, while the test sample was used to evaluate the model 
performance on a previously unseen data. 
RF requires input of the number of decision trees to grow for each run and the number of 
features to be used for each tree. After model training and tuning, the number of trees for each 
run was determined to be 100 and the number of features was set to five. The trained fully 
adjusted model and the model with top 20 predictors were then tried in the test data and 
prediction accuracy was computed for the treatment outcome. The area under the curve (AUC) 
was calculated to assess the performance of the predicting models and measures of 
discrimination, including sensitivity and specificity are reported. To facilitate model 
interpretation, the adjusted odds ratio and their 95% confidence intervals computed from 
performing logistic regression of the final model are presented for the top predictors identified 
from the machine learning method. Dataset construction was performed using SAS 9.4 (Cary, 
NC) and all predictive modeling was performed in R software (R Development Core Team, 
Vienna, Austria). 
Predictors (i.e. Features) of TRD for Inclusion in the Model 
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While feature selection can be performed using automated methods, many experts 
suggest that variable selection should be supported by expert knowledge or conceptual 
frameworks, whenever feasible.87 Initial selection of the plausible predictors of TRD (n=42) was 
based on the Determinants of Health Outcomes and Chronic Disease conceptual framework,63 
that included the following dimensions: 1) biological risk factors, 2) access to care factors (e.g. 
type of plan and co-pay), 3) disease and health- related factors 4) treatment-related factors 
(MDD-related treatment, pain-related treatment, and other treatment factors), and 5) community 
resources. For a comprehensive list of all predictors see Table 2.1. While most variables were 
measured during the baseline period, MDD-treatment related variables were measured during the 
follow-up period, before TRD measurement. In order to ensure that all included variables were at 
least plausible predictors of TRD, a manual variable selection was performed using an extensive 
literature review and a conceptual framework adapted from the modified Determinants of Health 
Outcomes and Chronic Disease conceptual framework. 63 
 Biological factors included age and sex. Predictors included in access to care domain 
were the type of plan, and out of pocket payment (calculated using co-pay, co-insurance and 
deductible for healthcare services). Disease-related factors included type and number of CNPC 
and health-related factors included other chronic conditions, obesity, substance use disorders 
(including tobacco use disorder, alcohol use disorder, and drug use disorders). All health-related 
factors were measured using ICD-9 or ICD-10-CM codes as appropriate. Pain-related treatment 
factors included commonly used pain medications such as opioid use, and NSAID use. MDD-
related treatment factors included mental health specialist visits, inpatient status, use of 
psychotherapy after MDD diagnosis, and class of index antidepressant medication. Other 
treatment-related factors included primary care provider visits, polypharmacy (defined as 
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concomitant use of > 5 medications within 90 days)88, and use of medications that may have 
depression as a side-effect (included fills for benzodiazepines, analgesics such as NSAIDs and 
opioids, statins, corticosteroids, and beta blockers).36 
Model Development 
 To identify an abbreviated set of factors that can increase the utility of the predictive 
model for providers and other stakeholders, a more refined model was built using basic filter 
method such as chi-square for categorical variables and pearson’s correlation for continuous 
variables. Further, an alternative wrapper feature selection method using logistic regression was 
used, wherein the performance of regression models with subsets of variables is assessed in 
random subsets of data.89 Feature selection yielded a total of 20 variables for inclusion in the 
refined model. Figure  in the Appendix 7.3 illustrates the process of variable selection and model 
development.  
2.4 Results 
 Characteristics of the study sample (total N=23,645) are summarized in Table 2.2. 
Majority were females (73.3%) and the mean age of patients was 55.36 years. Arthritis/joint pain 
was the most commonly observed pain condition (91%) followed by back/neck pain (71%). A 
large proportion of study sample reported > 2 CNPC conditions (78%). The most commonly 
observed other chronic conditions were cardiovascular conditions (38.4%) and anxiety (27.6%). 
About one forth of the study subjects used pain medications such as opioids (28.7%) and 
NSAIDs (25.5%). 
In our study sample, 2,684 patients (11.4%) had TRD within one year after MDD 
diagnosis. About 3.3% of the study sample augmented antidepressants with an atypical 
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antipsychotic or a mood stablizer and only 11 patients were found to be using electroconvulsive 
therapy within one year of MDD diagnosis. (Supplementary Information, Appendix 7.4)    
There were statistically significant differences in TRD status (Table 2.2) by age, type and 
number of CNPC, other chronic conditions such as anxiety, presence of sleep disorders, 
substance use disorders, polypharmacy, and use of MDD-related treatment factors (All p < 
0.001). For example, the prevalence of TRD was significantly higher among younger adults (35-
44 years old) as compared to those with age > 65 years (13.0% vs. 9.2%), among those with 
anxiety (15.3% vs. 9.9%), with >3 CNPC conditions (14.1% vs. 9%) as compared to those with 
one CNPC. A significantly higher proportion of adults with TRD had drug use disorder (19.8% 
vs. 11.0%), used polypharmacy (14.9% vs. 8.5%), and benzodiazepines in the baseline period 
(15.4 % vs. 9.8%). Additionally, greater proportions of adults having inpatient hospitalizations, 
and mental health specialist visits within 90 days of MDD diagnosis had TRD as compared to 
those having no inpatient or mental health specialist visits (p < 0.001). Adults who were 
prescribed SSRI as the first antidepressant after MDD diagnosis had lower prevalence of TRD, 
whereas those whose index prescription belonged to the class of other antidepressants and TCAs 
had higher prevalence of TRD (p < 0.001). 
             The fully-adjusted predictive model as well as the reduced predictive model with top 20 
features had fairly modest discriminatory model performance. The AUC obtained from the RF 
model for the training data was 0.716 and 0.70 for the fully-adjusted and refined models 
respectively. The out of bag (OOB) error, which is an indicator of  the unbiased estimator of true 
error rate, ranged from 11.4% -11.5%. Similar model performance was observed in the test data 
(Supplemental information, Appendix 7.5). The AUC for the RF and LR models were similar. 
The AUC from the training sample for the fully adjusted LR model was 0.711 for the fully-
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adjusted model and 0.704 for the refined model and from the test sample for the fully adjusted 
and refined models was 0.708 and 0.705 respectively. 
             The average importance values obtained from LR and RF for the highest scoring top 10 
predictors of TRD are represented in Figure 2. Overall, mental health specialist visits, 
polypharmacy, psychotherapy use, presence of anxiety, younger age, index antidepressant class, 
sex, any IP hospitalization after MDD diagnosis, number of CNPC, and benzodiazepine use were 
the leading predictors of TRD in both RF and LR, although ordering were slightly different. 
              For ease of interpretation and for comparison with published literature, Table 2.3 
summarizes the adjusted odds ratios (AOR) and their associated 95% CIs obtained from logistic 
regression of the final refined model (model with top 20 features). For example, adults visiting 
mental health specialists within 90 days of MDD diagnosis were almost two times more likely to 
develop TRD, as compared to those not having mental health specialist visits (AOR = 1.93; 95% 
CI = 1.7-2.18). Adults using psychotherapy after MDD diagnosis (AOR=1.36, 95% CI=1.20-
1.55) and those using > 5 different types of medications concomitantly in a period of 90 days 
(AOR=1.81, 95% CI=1.62-2.03) were more likely to develop TRD, as compared to their 
counterparts without these characteristics. 
2.5 Discussion 
To our knowledge, this is the first study using large administrative claims data to identify 
leading predictors of TRD among commercially insured adults CNPC and newly diagnosed 
MDD. In the current study, approximately one in nine adults (11.4%) with CNPC and newly 
diagnosed MDD transitioned to TRD within 1 year. This estimate is consistent with previously 
reported estimates for TRD prevalence among adults with MDD which ranged from 6% to 
30%.22,23,29,44  It has to be noted that TRD rates from our study are not directly comparable to 
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published studies due to differences in study population as our study sample was restricted to 
adults with CNPC and newly diagnosed MDD. Our estimate of 11.4% for TRD prevalence, 
which was identified using a clinical staging claims algorithm,23,61  was in line with a recent 
study that reported the prevalence rate of TRD as 11% using the Optum database. It has to be 
noted that the previous study used a slightly different definition for identifying TRD subjects as 
those with at least three distinct trials of antidepressants or those who augmented antidepressants 
with antipsychotics.29  
Consistent with published literature we found age to be a leading predictor of TRD.29,30 It 
has been reported in literature that TRD has been linked to an earlier age of onset of 
depression,90,91 and our study findings further support this. Sex has not been previously reported 
as a leading predictor of TRD. 26,27,29,50 However, the relevance of sex in this patient population 
is not new.22, 51, 55 This finding could perhaps be attributed to the higher prevalence and risk of 
both MDD as well as chronic pain among females, as compared to males.22,30,92 It has to be noted 
that our study sample was overwhelmingly female (73%), which is comparable to the 61% -71% 
prevalence estimates of females in studies conducted among all adults with MDD.22,29,41 
 Our findings demonstrated that in clinical settings, a smaller set of MDD treatment-
related factors around the time of MDD diagnosis can be used to predict the risk of transitioning 
from MDD to TRD.  These included the class of first prescribed antidepressant after MDD 
diagnosis, mental health specialist visits, and psychotherapy use within the first 90 days after a 
MDD diagnosis. Specifically, we found that adults with CNPC who used SSRIs, the most 
frequently prescribed antidepressants,93 as their index antidepressant were less likely to transition 
from MDD to TRD. Existing studies on association between  the specific type of antidepressants 
and outcomes in patients with TRD had a very small sample size and resulting conclusions 
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should be taken cautiously.74 In light of the findings from the current study, future research is 
warranted to understand the association between types of antidepressants with TRD. The 
predictors such as mental health specialist visits and psychotherapy use are often indicative of 
greater depression severity.94As patients with more severe MDD or patients with poor response 
to antidepressants may have a higher chance of visiting a mental health specialist or using 
psychotherapy as additional treatment,94 they may have a higher risk of TRD. 
The current study identified anxiety as well as benzodiazepine to be predictors of TRD. 
While, comorbid anxiety disorder has been consistently reported by several studies as a risk 
factor for TRD, 26,74,90,91 association of benzodiazepine use with TRD has not been investigated 
in prior literature. Treatment becomes challenging when pain, often experienced by those with 
CNPC and MDD, overlap with anxiety.  Researchers have highlighted the reciprocal interactive 
relationships between pain, anxiety and depression.51,91 It is plausible that anxiety is a risk factor 
for TRD because comorbid anxiety disorder and MDD in patients with CNPC is often associated 
with higher symptom severity and poor response to depression treatment.51,91 Benzodiazepines 
are commonly used medications for anxiety and sleep disorders, both common comorbid 
conditions among patients with CNPC and MDD. In fact, studies have shown that the use of 
benzodiazepines is significantly higher among patients with chronic pain.95,96 Previous research 
has documented a high prevalence of benzodiazepine use among women, especially older 
women, and among opioid users.97,98 Despite several major medical and psychiatric 
organizations advising against using benzodiazepines among elderly and in combination with 
opioids, benzodiazepines continue to be prescribed. This may lead to high risks and serious 
adverse effects among vulnerable groups.99, 96 Benzodiazepine use as a predictor of TRD further 
reinforces the need to weigh the risk versus benefits of prescribing benzodiazepines among 
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adults with CNPC and newly diagnosed MDD. Our findings suggest that patients with CNPC, 
MDD and anxiety disorders need to be monitored more closely and that there is a need for 
evaluating alternative treatment strategies that can help in the co-management of these 
conditions.   
We also identified the number of CNPC conditions as an important predictor of TRD. 
Higher number of CNPC conditions may indicate multisite chronic pain and may result in 
increased pain severity which is a strong predictor of poor depression outcomes.11 Studies have 
also reported that chronic pain was associated with increased severity of depression and 
insufficient response to antidepressants.11,100 Several large clinical trials on chronic pain often 
exclude patients with MDD, 101 and therefore lack of data on treatments that can be used to co-
manage both pain and MDD continues. Our findings underscore the need for effective 
pharmacological treatments for managing both pain and MDD symptoms. 
Our predictive models identified polypharmacy (excluding the use of antidepressants) as 
one of the top five predictors of TRD. Pain medications are commonly used to relieve pain 
among patients with CNPC. While we did not find individual pain medications such as NSAIDs 
and opioids as risk factors for TRD, a combination of medications may increase the potential 
exposure to side-effects and harm due to drug-drug interactions. In fact, a recent study which 
characterized polypharmacy among patients with CNPC suggested that a majority of medication 
related-harm exposure was also attributed to medications other than opioids, such as simple 
analgesics, benzodiazepines, and number of medications used concomitantly.75 Higher number 
of concomitant medication use is also indicative of the presence of multiple chronic conditions 
which are more common in patients with TRD, as compared to those without TRD.20   
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Although machine learning methods and standard logistic regression method yielded 
similar model performance, adoption of RF and LR machine learning approaches enabled us to 
perform robust feature selection and in identifying the most important predictors out of an 
extensive set of 40 features. The model performance of fully adjusted as well as with a reduced 
set of 20 variables was comparable and fairly modest. A reduced set of top n features (n=20) 
helps in focusing on the most important predictors of TRD and is more practical if one was to 
design a new study and collect features to predict TRD among CNPC patients. 
2.6 Limitation 
Although a rigorous methodology was utilized to design and execute the study, the 
findings of this study need to be interpreted in the context of its limitations. The study suffers 
from inherent limitations associated with claims data analysis, including coding inaccuracies, 
absence of information on severity of MDD, socioeconomic status, race/ethnicity, physical 
activity, and social support. Furthermore, our algorithm used to identify MDD naïve patients (a 
look-back period of 180 days) may not truly capture all incident MDD patients. For patients 
having multiple MDD episodes in the study period, we selected the very first episode, however, 
it is possible that they could have received diagnosis or treatment elsewhere, which could not 
have been captured in the current claims. It has to be noted that lack of availability of severity of 
MDD and pain may have resulted in unobserved selection bias. Further, we may not have truly 
captured the actual use of prescription medication as the drug claims provide information on only 
filled prescriptions and not actual use. 
Although we identified leading predictors of TRD in a sample of CNPC patients with 
newly diagnosed depression, the model had a much better discriminative power to predict non-
TRD cases as compared to TRD cases. One plausible explanation is that published prediction 
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models with better sensitivity to identify TRD cases used data from participating clinical centers 
across Europe or clinical trial data which predicted TRD among prevalent cases of MDD. This 
can provide information on the number of past depressive episodes, severity of MDD, and other 
clinical parameters which could not be captured via administrative claims data.26-28,73 
Additionally, in actual clinical practice, adults with TRD are identifying using detailed clinical 
criteria such as responsiveness to medical treatments, and tolerance to antidepressants, which 
were not available in claims data. Therefore, we may have either underestimated or 
overestimated the prevalence of TRD. The models were refined and tested in unique sub-sample 
that was created from the same overall sample as the training data. The validity of the model and 
the leading predictors obtained from the models will be more generalizable if applied to datasets 
with patients with CNPC obtained from different samples, specifically other commercial 
administrative databases. 
2.7 Conclusion 
Notwithstanding the limitations, our study provides important insights on factors that 
may predict the transition from MDD to TRD among patients with CNPC using a large 
population-based real-world study. We identified biological and health-related factors unique to 
CNPC who developed MDD such as number of CNPC conditions, age, sex, other chronic 
conditions such as anxiety, polypharmacy and factors related to MDD treatment and severity 
such as mental health specialist visits, use of psychotherapy, and class of index antidepressant as 
leading predictors of TRD. These factors can serve as targets for future studies to further 
understand TRD and can help in developing healthcare and clinical interventions to improve 
treatment outcomes in patients with CNPC and MDD. 
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Figure 2.1 Schematic presentation of study sample selection-Inclusion and exclusion 
criteria applied to patients with CNPC and newly diagnosed episode of MDD, Optum 
Clinformatics Data Mart, observation period January 2007-June 2017. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients with MDD in years 2008-2016 
N=683,701 
Patients with CNPC diagnosis in baseline period 
N=271,493 
Those with MDD but no 
CNPC (N=412,208) 
N=683,701 
Cancer Free 
N=201,955 
Had cancer (N=69,538) 
Patients without schizophrenia, schizoaffective, 
manic depression or bipolar disorder 
N=192,328 
Patients with conditions 
that could complicate TRD 
assessment (N=9,627) 
 
Patients with newly diagnosed MDD episode 
(No MDD diagnosis or antidepressant 
prescription in prior 180 days) 
N=90,937 
Patients without incident 
MDD (N=101,391) 
Patients receiving antidepressant treatment (at 
least 1 antidepressant fill after MDD diagnosis) 
N=50,664 
Final analytical sample: Patients aged >18 
years with continuous enrollment 12 months 
before and 12 months after the index date 
N=23,645 
Patients with no 
antidepressant claims 
(N=40,273) 
 Adults without continuous 
enrollment (N=27,009) 
and those with unknown 
information on sex 
variable (N=10) 
With TRD 
N=2,684 
Without TRD 
N=20,961 
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Table 2.1. List of All 42 Predictors Considered for Model Inclusion Described by the Conceptual 
Framework Dimensions 
Dimension Predictors 
Biological risk factors (N=2) Age, sex 
Access to care factors (N=3) Medicare enrollment, (commercial, Medicare advantage), plan type a (HMO, 
PPO/POS, other), out of pocket payment 
Disease and Health-related 
factors (N=18) 
Type of CNPC (grouped into commonly occurring CNPC conditions including 
back/neck pain, arthritis/joint pain, headache/migraine, neuropathic/other 
chronic pain), number of CNPC conditions, chronic conditions including 
anxiety, respiratory conditions (asthma and COPD), hypertension, 
cardiovascular conditions b, dementia, diabetes, other mental illness, 
osteoporosis, sleep disorder, obesity diagnosis, tobacco use disorder, alcohol 
use disorder, drug use disorder 
Treatment-related factors 
(MDD -related, pain- related 
and other treatment factors) 
(N=17) 
 
Pain – related treatment (included NSAID use, opioid use), use of 
psychotherapy before MDD diagnosis, polypharmacy c, use of medications 
associated with depression including benzodiazepines, corticosteroids, beta 
blockers, and statins, primary care provider visits, mental health specialist 
visits, use of psychotherapy after MDD diagnosis, any inpatient 
hospitalizations, hospitalizations related to MDD, class of index antidepressant 
(SSRI, SNRI, TCA, Other)d 
Community resources(N=1) geographical region (region derived from state variable) 
Other predictors(N=1) index year 
a HMO: Health Maintenance Organization, PPO: Preferred provider organization, POS: Point of service, other plan 
type includes fee-for-service, indemnity plans, EPO (exclusive provider organization), GPO (Group purchasing 
organization), IPP (individual program plan), and other plans, CNPC: Chronic non-cancer pain conditions, NSAID: 
Non-steroidal anti-inflammatory drugs 
b Cardiovascular conditions included hyperlipidemia, ischemic heart disease, coronary artery disease, congestive 
heart failure, myocardial infarction, and stroke 
c Polypharmacy was defined as concomitant use of 5 or more medications within a 90-day period 
d SSRI: Selective serotonin reuptake inhibitors, SNRI: Serotonin norepinephrine reuptake inhibitors, TCA: tricyclic 
antidepressants, other: includes medications such as bupropion, mirtazapine, nefazodone, trazadone, vilazodone, and 
vortioxetine. 
Note: MAOI (monoamine oxidase inhibitors) are not included as a predictor because of very small sample size 
(N=4) 
Note: Predictors related to MDD treatment such as use of psychotherapy, index antidepressant, mental health 
specialist visits, hospitalizations were measured in acute phase of MDD treatment, i.e. first 90 days after MDD 
diagnosis. 
  35 
Table 2.2. Description of Adults with CNPC and Newly Diagnosed MDD by TRD  
 Optum Clinformatics Real-World De-identified Data, 2007-2017 
    
Overall 
(N=23,645) 
Patients classified as TRD (N=2,684)       
Overall 
(N=23,645) 
Patients classified as TRD 
(N=2,648) 
  
Characteristics N %  N  Row% 
Chi sq 
statistic 
P value Sig 
Characterist
ics 
N %  N  Row% 
Chi sq 
statistic 
P value Sig 
Index Year     10.512 0.005 ** Obesity diagnosis    1.479 0.224   
  2008-2010 6257 26.5 747 11.9     
 Yes 3842 16.2 458 11.9     
  2011-2013 7077 29.9 845 11.9      No 19803 83.8 2226 11.2     
  2014-2016 10311 43.6 1092 10.6     Sleep disorder    83.738 <0.001 *** 
Region     6.289 0.098   
 Yes 5445 23 806 14.8     
  Northeast 2170 9.2 278 12.8      No 18200 77 1878 10.3     
  Midwest 5871 24.8 673 11.5     Tobacco use disorder    25.03 <0.001 *** 
  South 9544 40.4 1076 11.3      Yes 2399 10.1 346 14.4     
  West 6060 25.6 657 10.8      No 21246 89.9 2338 11     
Sex     8.181 0.004 ** Alcohol use disorder    11.563 <0.001 *** 
  Female 17340 73.3 2030 11.7     
 Yes 606 2.6 95 15.7     
  Male 6305 26.7 654 10.4     
 No 23039 97.4 2589 11.2     
Age group     57.418 <0.001 *** Drug use disorder    72.05 <0.001 *** 
  18-34 years 3127 13.2 351 11.2      Yes 975 4.1 193 19.8     
  35-44 years 3616 15.3 470 13      No 22670 95.9 2491 11     
  45-54 years 4706 19.9 596 12.7     Polypharmacy (>5 medications)   233.981 <0.001 *** 
  55-64 years 4468 18.9 554 12.4      Yes 10529 44.5 1566 14.9     
  >65 years 7728 32.7 713 9.2      No 13116 55.5 1118 8.5     
Medicare Enrollment   1.718 0.19   NSAID use 
  
  10.783 0.001 ** 
  Commercial 14216 60.1 1645 11.6      Yes 6036 25.5 755 12.5     
  
Medicare 
Advantage 
9429 39.9 1039 11      No 17609 74.5 1929 11 
  
  
Insurance plan 
type     
2.064 0.356   Opioid use   
  5.188 0.023 * 
  HMO 7439 31.5 819 11      Yes 6789 28.7 760 12.6     
  PPO/POS 11317 47.9 1319 11.7      No 16856 71.3 1790 11.5     
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  Other 4889 20.7 546 11.2     Beta blocker use    15.698 <0.001 *** 
Back/neck pain     30.475 <0.001 *** 
 Yes 4795 20.3 622 13     
  Yes 16845 71.2 2034 12.1      No 18850 79.7 2062 10.9     
  No 6800 28.8 650 9.6     Statin use     0.006 0.938   
Headache/ 
migraine     
48.543 <0.001 ***  Yes 6557 27.7 746 11.4 
  
  
  Yes 7849 33.2 1051 13.4     
 No 17088 72.3 1938 11.3     
  No 15796 66.8 1633 10.3     Benzodiazepine use 
 
  144.594 <0.001 *** 
Arthritis/Joint 
Pain     
3.635 0.057    Yes 6550 27.7 1006 15.4 
  
  
  Yes 21535 91.1 2471 11.5     
 No 17095 72.3 1678 9.8     
  No 2110 8.9 213 10.1     Corticosteroid use 
 
  3.463 0.063   
Neuropathic pain/other chronic pain  48.733 <0.001 *** 
 Yes 2697 11.4 335 12.4     
  Yes 5417 22.9 758 14     
 No 20948 88.6 2349 11.2     
  No 18228 77.1 1926 10.6     Psychotherapy before MDD   36.021 <0.001 *** 
No. of CNPC     95.738 <0.001 *** 
 Yes 1132 4.8 191 16.9     
  1 5217 22.1 469 9     
 No 22513 95.2 2493 11.1     
  2 10469 44.3 1095 10.5     Psychotherapy after MDD†  182.284 <0.001 *** 
  >3 7959 33.7 1120 14.1     
 Yes 4653 19.7 790 17     
Anxiety     137.811 <0.001 *** 
 No 18992 80.3 1894 10     
  Yes 6520 27.6 996 15.3     Mental health specialist visit†   437.948 <0.001 *** 
  No 17125 72.4 1688 9.9     
 Yes 5536 23.4 882 20.5     
Dementia     23.516 <0.001 *** 
 No 18109 76.6 1802 9.3     
  Yes 1058 4.5 169 16     Primary care provider visit†   12.887 <0.001 *** 
  No 22587 95.5 2515 11.1     
 Yes 19892 84.1 2194 11     
Other mental illness    78.067 <0.001 *** 
 No 3753 15.9 490 13.1     
  Yes 703 3 153 21.8     Any Inpatient hospitalizations†   108.362 <0.001 *** 
  No 22942 97 2531 11     
 Yes 2593 11 453 17.5     
Respiratory conditions   33.582 <0.001 *** 
 No 21052 89 2231 10.6     
  Yes 3003 12.7 435 14.5     MDD related Inpatient hospitalizations†  94.058 <0.001 *** 
  No 20642 87.3 2249 10.9     
 Yes 1116 4.7 227 20.3     
Cardiovascular conditions   1.018 0.313   
 No 22529 95.3 2457 10.9     
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  Yes 9091 38.4 1008 11.1 
  
  
Index Antidepressant class: 
SSRI† 
 
 
338.287 <0.001 *** 
  No 14554 61.6 1676 11.5     
 Yes 12912 54.6 1019 7.9     
Hypertension     1.028 0.311   
 No 10733 45.4 1665 15.5     
  Yes 9284 39.3 1078 11.6 
  
  
Index Antidepressant class: SNRI 
† 
 
 
0.903 0.342   
  No 14361 60.7 1606 11.2     
 Yes 3277 13.9 388 11.8     
Diabetes     0.081 0.776   
 No 20368 86.1 2296 11.3     
  Yes 4771 20.2 536 11.2 
  
  
Index Antidepressant class: 
TCA† 
 
 
32.558 <0.001 *** 
  No 18874 79.8 2148 11.4     
 Yes 982 4.2 167 17     
Osteoporosis     2.571 0.109   
 No 22663 95.8 2517 11.1     
  Yes 825 3.5 108 13.1 
  
  
Index Antidepressant class: 
Other† 
 
 
300.73 <0.001 *** 
  No 22820 96.5 2576 11.3     
 Yes 5094 21.5 926 18.2     
           
 No 18551 78.5 1758 9.5     
    Overall (N=23,645) 
Patients classified with TRD 
(N=2,684) 
Patients without TRD (N=20,961)         
Continuous 
variable 
Mean SD Mean SD Mean SD T statistic P value Sig 
Age 55.36 17.64 53.67 16.88  55.57  17.71 5.48 <0.001 *** 
Out of pocket 
cost per month^ 
$928.68  $6,337  $933.30  $3,122.10  $928  $6,337.90  0.05 0.95   
Note: Based on 23,645 adults with CNPC and newly diagnosed MDD receiving antidepressant medication treatment with continuous enrollment for 12 months baseline and 12 months 
follow-up periods in a commercial insurance plan, years 2007-2017 
MDD: Major Depressive Disorder, TRD: Treatment resistant depression, CNPC: Chronic non-cancer pain conditions, HMO: Health Maintenance Organization, PPO: Preferred provider 
organization, POS: Point of service, other plan type includes fee-for-service, indemnity plans, EPO (exclusive provider organization), GPO (Group purchasing organization), IPP(individual 
program plan), and other plans, NSAID: Non-steroidal anti-inflammatory drugs, SSRI: Selective serotonin reuptake inhibitors, SNRI: Serotonin norepinephrine reuptake inhibitors, TCA: 
tricyclic antidepressants, other: includes medications such as bupropion, mirtazapine, nefazodone, trazadone, vilazodone, and vortioxetine. 
Respiratory conditions included chronic obstructive pulmonary disease (COPD) and asthma 
Cardiovascular conditions included hyperlipidemia, ischemic heart disease, coronary artery disease, congestive heart failure, myocardial infarction, and stroke 
Polypharmacy was defined as concomitant use of 5 or more medications within a 90 day period 
†Represents all MDD treatment related variables that were measured in the acute phase after MDD diagnosis i.e. first 90 days after MDD index date 
^Average out of pocket costs are represented only for those incurred any out of pocket expenditure (N=13,752) 
*** p < .001;  ** .001 ≤ p < .01; * .01 ≤ p < .05 
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Figure 2.2 Variable importance values for top 10 variables of TRD among patients with 
CNPC and newly diagnosed MDD obtained from Machine Learning Approaches: A) 
Logistic regression B) Random forest models 
 
Figure 2.2.A  
 
Figure 2.2.B  
 
Note: Predictors are listed on the Y axis by increasing impact of importance from the top to bottom. 
CNPC: Chronic non-cancer pain conditions, IP: Inpatient, SSRI: Selective serotonin reuptake inhibitors 
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Table 2.3. Adjusted Odds Ratio and 95% Confidence Intervals for Important Predictors of 
TRD from Logistic Regression Model for Adults with CNPC and Newly Diagnosed MDD  
Optum Clinformatics Real-World De-identified Data, 2007-2017 
Predictor AOR 95% CI P value 
Mental health provider visit (yes vs. no) 1.93 1.70-2.18 <0.001 
Polypharmacy (yes vs. no) 1.81 1.62-2.03 <0.001 
Use of psychotherapy after MDD diagnosis (yes vs. 
no) 
1.36 1.20-1.55 <0.001 
Anxiety (yes vs. no) 1.27 1.13-1.41 <0.001 
Age (35-44 years vs. ≥ 65 years) † 1.41 1.19-1.66 0.002 
Age (18-34 years vs. ≥ 65 years) † 1.32 1.1-1.58 <0.001 
Index Antidepressant class: SSRI (yes vs. no) 0.69 0.60-0.79 <0.001 
Sex (female vs. male) 1.27 1.13-1.42 <0.001 
Any IP hospitalization (yes vs. no) 1.26 1.11-1.48 <0.001 
Index Antidepressant class: other (yes vs. no) 1.38 1.12-1.7 <0.001 
No. of CNPC conditions (≥3 vs. 1) 1.23 1.09-1.39 <0.001 
Benzodiazepine use (yes vs. no) 1.18 1.05-1.32 <0.001 
Note: Based on 23,645 adults with CNPC and newly diagnosed MDD receiving antidepressant medication 
treatment with continuous enrollment for 12 months baseline and 12 months follow-up periods in a 
commercial insurance plan, years 2007-2017 
MDD: Major Depressive Disorder, TRD: Treatment resistant depression, CNPC: Chronic non-cancer pain 
conditions, SSRI: Selective serotonin reuptake inhibitors, other antidepressants: includes medications such 
as bupropion, mirtazapine, nefazodone, trazadone, vilazodone, and vortioxetine, IP: Inpatient, AOR: 
Adjusted odds ratio, CI: Confidence Interval 
† Only age groups with p< 0.01 is presented 
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CHAPTER 3  
3 Economic Burden of Treatment-Resistant Depression among Adults with Chronic Non-
Cancer Pain Conditions and Major Depressive Disorder 
3.1 Abstract 
Objective: Treatment-resistant depression (TRD) in adults with chronic non-cancer pain 
conditions (CNPC) can amplify the economic burden. This study examined the impact of TRD 
on direct total and MDD-related healthcare resource utilization (HRU) and costs among patients 
with CNPC and MDD. 
Methods: The study used a retrospective longitudinal cohort design and employed a claims-
based algorithm to identify adults with TRD from a US claims database (January 2007- June 
2017). HRU and costs were measured over a 12-month period after TRD/non-TRD index date. 
Counterfactual recycled predictions from multivariable generalized linear models were used to 
examine associations between TRD and annual HRU and costs. Post-regression linear 
decomposition identified differences in patient-level factors between TRD and no TRD group 
that contributed to the excess economic burden of TRD.  
Results: Of the 21,180 adults with CNPC and MDD, 10.1% were identified as having TRD. 
TRD patients had significantly higher HRU, translating into higher average total costs 
($21,015TRD vs $14,712No TRD) and MDD-related costs ($1,201TRD vs $471No TRD) compared to 
non-TRD counterparts (all P <0.001). TRD patients had significantly higher number of inpatient 
visits (IRR = 1.30. 95% CI = 1.14-1.47; P<0.001) than non-TRD patients. Overall, 46% of the 
excess total costs were explained by differences in patient level characteristics such as 
polypharmacy, number of CNPC, anxiety, sleep, and substance use disorders between the TRD 
and no TRD groups. 
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Conclusion: TRD poses a significant direct economic burden among adults with CNPC and 
MDD. Excess healthcare costs may potentially be reduced by providing timely interventions for 
several modifiable risk factors. 
3.2 Introduction 
Major Depressive Disorder (MDD) is a highly prevalent mental disorder and presents a 
substantial economic burden.8,69 In 2015, the incremental economic burden of MDD in the 
United States (US) was estimated to be as high as $210.5 billion, with $98.9 billion spent on 
direct healthcare costs.8 Co-existence of MDD and chronic conditions has been reported to be the 
main driver of this high economic burden.8 For example, MDD is associated with 50% to 100% 
higher medical costs among patients with co-existing chronic conditions even after risk 
adjustments.10 Among commonly co-occurring chronic conditions with MDD, chronic non-
cancer pain conditions (CNPC) is of particular interest because of the high prevalence and well 
documented bi-directional relationship between MDD and pain.7,13,14 The prevalence of MDD in 
patients with CNPC can be as high as 85%. 7 CNPC and MDD are inextricably linked in terms of 
pain, biological pathways, and pathophysiology 14,15 which may contribute to the excess 
economic burden of MDD. A study documenting the excess costs of MDD across 11 chronic 
conditions including chronic non-cancer pain conditions (CNPC) such as osteoarthritis, joint 
pain, back pain, and headache highlighted a substantial economic burden of MDD.102 A handful 
of studies have also documented the excess economic burden of MDD among adults with CNPC, 
47,103 which may be in part explained by the additive adverse effects of MDD and CNPC on 
clinical outcomes.103,104  
Additionally, the economic burden of MDD and CNPC may be amplified for patients 
whose MDD is resistant to depression treatment. 11 It has been documented that patients with 
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CNPC may not respond adequately to antidepressants, a major modality of depression treatment, 
which can subsequently increase the risk of treatment-resistant depression (TRD).11 TRD is 
primarily MDD in which patients do not achieve remission even after undergoing multiple 
repeated and vigorous antidepressant treatment trials. 21,105 Studies have highlighted a high 
prevalence of TRD among adults with CNPC.20,22,24,29 As adults with TRD tend to have much 
longer episodes of depression, higher symptom severity, and higher healthcare resource 
utilization (HRU), the association of TRD with high economic burden has been documented in 
studies that are not specific to CNPC. 20,27,106 For example, adults with TRD had two times 
higher direct healthcare costs and higher HRU as compared to adults without TRD. 25,41,42,44,46 
However, to-date, no study has examined the economic burden of TRD among adults with 
CNPC and MDD. 
Estimating the economic burden of TRD in CNPC patients is important for several 
reasons: 1) Many policy initiatives have shifted focus to the pursuit of triple aim of improving 
the health of patients, quality of care and reducing healthcare costs,48 which  requires 
identification of high-cost, high-need patients;48 2) Payment reforms have focused on 
reimbursement methods such as bundled payments for episodes of care which require risk 
adjustment to account for differences in beneficiary-case mix. An up to date risk-adjusted 
estimate of economic burden for those with MDD should also include excess costs due to TRD; 
3) Helps in understanding their unmet needs, demonstrate the value for the need of targeted 
interventions and increased investments in mental health resources in this population; and 4)  
quantification of incremental burden of illness of TRD helps in translating the burden of illness 
into dollar terms, the universal language for decision making.49 
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Furthermore, TRD can be influenced by many factors.20,27,29,50  Therefore, it is important 
to estimate how much of the excess economic burden can be explained by differences in patient-
level characteristics between those with TRD and non-TRD patients. Understanding factors that 
can contribute the excess economic burden of TRD can aid payers in identifying major cost 
drivers. Therefore, the main objectives of this study were: to estimate the excess economic 
burden (direct healthcare utilization and costs) associated with TRD and to examine the extent to 
which differences in patient factors between TRD and no TRD groups contribute to the excess 
cost burden of TRD by using a post-regression linear decomposition approach among 
commercially insured adults with CNPC and newly diagnosed MDD. 
3.3 Methods  
Data Source 
This study was conducted using health insurance claims data (January 2007 through June 
2017) from the de-identified Optum® Clinformatics® Data Mart. 67 We used the 10% random 
sample of Optum data, which is a geographically diverse database, spanning across all 50 states. 
It contains information on diagnoses, procedures, treatment, medication use, and costs derived 
from inpatient, outpatient and pharmacy claims. Demographic characteristics (age, sex, state of 
residence), and health plan information are also routinely collected during health insurance 
enrollment. 67  
Study Design  
 
This study utilized a retrospective longitudinal cohort design. The study period consisted 
of cohort identification, baseline, and follow-up periods. The cohort identification period was 
used to identify adults with CNPC and newly diagnosed MDD.  The baseline period, defined as 
12 months before TRD index date (randomly imputed pseudo-index date for non-TRD) was used 
to identify independent variables, including baseline HRU and costs. The follow-up period (12 
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months after TRD index/pseudo-index date) was used to compute the economic outcomes (HRU 
and direct costs). 
Cohort Selection 
 
The study cohort comprised adults with CNPC and newly diagnosed MDD (identified 
using ICD9/10 codes) between January 2008 and June 2016 (Appendix 7.1). Adults with CNPC 
were required to have at least two or more healthcare encounters during the cohort identification 
period (i.e 12 months before the first observed MDD diagnosis). CNPC was identified using an 
extensive list of conditions for which pain was severe enough to classify them as chronic pain 
condition. 80-82 To ensure that the episode of MDD was newly diagnosed, we used a validated 
algorithm of including only those who did not have any MDD diagnosis or antidepressant 
prescription in 180 days prior to the MDD diagnosis date.78,79 
We used the following additional inclusion-exclusion eligibility criteria to identify the 
study cohort:1) adult patients (age > 18 years) with at least one antidepressant prescription 
following MDD diagnosis, 2) no diagnosis for cancer throughout the study period, 3) consistent 
with prior studies, those with a diagnosis of schizophrenia, schizoaffective disorder, other 
psychosis, manic depression or bipolar disorders were excluded,22,23 4) continuous enrollment 
during the 12 months before MDD identification and 24 months after MDD identification. (See 
Figure 3.1 for number of individuals eliminated at each step of application of inclusion-exclusion 
criteria). The final sample consisted of 21,180 adults with CNPC and newly diagnosed MDD. 
Measures 
Key Independent Variable: Treatment-Resistant Depression 
 
We used a claims-based algorithm that was developed using the Massachusetts General 
Hospital (MGH) clinical staging method. 23,61 This claims-based algorithm has been previously 
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used to estimate the cost burden associated with TRD.23 Although previous studies using 
administrative claims data to study TRD has defined TRD using different definitions,22,23,41,42 we 
chose the MGH-based algorithm because it can be readily translated to prescription claims 
information. Furthermore, it encompasses the four main strategies to overcome lack of 
antidepressant treatment response, i.e. optimization, switching, combination, or augmentation. 62  
We defined TRD using a point-based algorithm; one point was assigned for each adequate 
antidepressant trial (i.e., 2 or more fills of the same antidepressant), and half a point for each 
optimization strategy. The optimization strategies included extended duration (i.e. at least 3 fills 
of the same antidepressant), an upward titration in dose, and augmentation with an atypical 
antipsychotic, mood stabilizer, or thyroid hormone. Individuals exceeding three points were 
considered to have TRD.23 Those using electroconvulsive therapy (ECT) were considered to 
have TRD as ECT is often used as a late-stage treatment for TRD. 7  
Study Outcomes 
 
HRU and Direct Healthcare Costs  
 Direct costs and HRU (here-after referred as costs and HRU) included both all-cause 
and MDD-related utilization and costs. For HRU, dependent variables were counts of total and 
MDD-related inpatient admissions, outpatient visits, and emergency department (ED) visit. 
Claims data from Optum are verified and adjusted with a standard pricing methodology to 
account for variations in allowed payments across health plans and provider contracts prior to 
inclusion in the Data Mart dataset. Total costs included allowed payments for inpatient stays, 
facility outpatient visits, professional services, and prescription drugs from the insurer. Allowed 
payments from the insurer were estimated and normalized to 2018 US dollars using the cost 
factors and standardized prices provided by Optum Clinformatics ® DataMart. MDD-related 
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costs and use were identified using the primary or secondary ICD-9/10 CM diagnosis codes 
indicating MDD (see Appendix 7.1 for code definitions). Utilization and costs were summed 
over a period of 12 months following TRD index/pseudo-index date 
Other independent variables (measured at baseline)  
 
The selection of other independent variables that could impact economic outcomes was 
guided by the Modified Andersen’s Behavioral Framework of Health Services Use.64 The model 
posits that the health services costs and utilization of an individual is primarily a function of 
predisposing factors (e.g., age, sex), enabling factors (e.g. type of insurance plan, Medicare 
advantage enrollment), need factors (e.g. chronic conditions, obesity, sleep disorders,  tobacco 
use disorder, and drug/alcohol use disorder, polypharmacy, benzodiazepine use, and use of pain 
medication such as opioids and NSAIDs), and external environment (e.g. geographical region). 
Chronic conditions included comorbid anxiety disorders, sum of CNPC conditions, and number 
of chronic physical conditions other than CNPC. Baseline cost and resource use was also 
measured.  
Statistical Analyses 
 
Baseline patient characteristics were compared between patients with and without TRD 
using chi-square test for categorical variables and t-test for continuous variables. Adjusted 
associations between TRD and HRU in the follow-up period was assessed using multivariable 
negative binomial regressions and the results are reported using incidence rate ratios (IRR) and 
95% confidence intervals (CI). The adjusted associations between TRD and healthcare costs 
were evaluated using two-part models (TPM). Because healthcare and MDD-related costs had 
zero mass (> 5%), we used two part models for all cost analyses107The first part of the model 
used a logistic regression to assess the association between TRD and any positive cost and the 
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second part of the model used generalized linear models (GLM) with a gamma distribution and 
log-link function to handle positively skewed cost distribution. Rather than simply comparing the 
expenditures between the groups for a reference case (i.e. marginal effects) robust estimates for 
incremental costs between TRD and non-TRD groups were obtained using the counterfactual 
recycled prediction technique from parameter estimates of GLM.108 Cost differences, p-values, 
and their adjusted 95% confidence intervals were obtained from nonparametric bootstrap 
procedures (500 replications). We present estimates from two models, one with risk-adjustment 
for the predisposing, need, and external environmental factors described above and other with 
additional risk adjustment for healthcare costs.  
To estimate the extent to which differences in patient-level characteristics between TRD 
and no- TRD groups contribute to the excess total costs associated with TRD, we use the 
Blinder-Oaxaca linear decomposition approach.109,110,111 This technique assesses how much of 
the difference in expenditures between the two groups may be due to observable or explained 
factors (e.g. the predisposing, enabling, need, and external environmental factors described 
above) versus unobservable or unexplained factors (e.g. lifestyle difference, social support, 
education, income).The explained portion can be interpreted as counter-factual scenario (i.e. 
estimated differences in cost burden if adults with TRD had the same characteristics as adults 
without TRD). All data management and analyses were performed with SAS 9.4 (SAS Institute 
Inc., Cary, NC) and Stata 14 (StataCorp LLC, College Station, TX).  
3.4 Results 
Sample Description 
  Of a total of 21,180 adults with CNPC and newly diagnosed MDD, 10.1% (N=2,147) 
adults transitioned from MDD to TRD within one year of MDD diagnosis. On average patients 
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identified as TRD were 53 years old and were predominately females (77%). The description of 
study sample characteristics and subgroup differences in characteristics of adults with and 
without TRD are presented in Table 3.1. Significant differences were observed in predisposing 
and need factors between TRD and non-TRD groups. For example, a significantly higher 
proportion of TRD patients had higher rates of polypharmacy (69.4% vs. 49.6%), had >3 CNPC 
(40.6% vs. 32.1%), had comorbid anxiety disorders (55.7% vs. 15.3%), had sleep disorders 
(33.6% vs. 23.7%), and drug/alcohol use disorders (15.9% vs. 8.1%) as compared to non-TRD 
patients (all P <0.001). The rates of baseline HRU were significantly higher among adults with 
TRD as compared to those without TRD (all P <0.001) (Table 3.1). 
HRU 
 Unadjusted (Appendix 7.8) and adjusted rates (Figure 3.2) of HRU during the follow-up 
period were higher for those with TRD as compared to those without TRD.  Adults with TRD 
had significantly higher number of inpatient (IRR = 1.30, 95% CI = 1.14 - 1.47) and ED visits 
(IRR = 1.21, 95% CI = 1.10-1.34) and higher MDD-related healthcare utilization (e.g. 3.0 and 
2.23 times the inpatient and ED visit rate) as compared to adults without TRD. 
Healthcare Costs 
We observed that the mean unadjusted total costs during the 12-month follow-up period 
(Table 3.2) were higher for adults with TRD as compared to those without TRD ($21,015TRD and 
$14,712No TRD), with an excess per patient cost of $6,303 (P <0.001). Prescription drug costs 
accounted for 37.6%, inpatient services for 30.7%, outpatient services for 21.3% and ED use for 
the remaining 10.6% of the excess TRD healthcare costs (can be calculated from Table 3.2). 
Similarly, adults with TRD had significantly higher unadjusted MDD-related costs as compared 
to adults without TRD ($1,201 vs. $471, P <0.001). Adults with TRD had significantly higher 
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costs for each component of all-cause and MDD-related costs as compared to adults without 
TRD (Table 3.2).  
Adjusted all-cause and MDD-related healthcare costs remained significantly higher 
(Model 1) for those with TRD as compared to adults without TRD, yielding an excess cost 
estimate of $3,388 for all-cause cost and $394 for MDD-related total costs. After additionally 
adjusting for baseline healthcare costs (Model 2), the excess TRD costs reduced to $2,025 (all-
cause) and $296 (MDD-related).  For all components of all-cause and MDD-related costs, those 
with TRD had higher costs compared to those without TRD (P<0.001) (Table 3.2). 
 Table 3.3 summarizes the results from the post-regression linear decomposition. Nearly 
half of the difference (46%) in total all-cause costs was explained by differences in the baseline 
characteristics between the TRD and no TRD groups. This means that if the TRD group were to 
have the same distribution of characteristics as the no-TRD group, 46% of the excess cost burden 
can be reduced. Among all patient level factors, need factors, specifically differences in 
polypharmacy rates contributed to over half (55.7%) of the explained portion of the total costs. 
Other contributors to the excess cost burden were: number of CNPC (11.24%), tobacco and drug 
use disorders (10.99%), and presence of sleep and anxiety disorders (8.17%). When baseline 
costs were added to the model, it explained 65% of the difference in total healthcare costs 
between the two groups (data not provided in tabular form). 
Secondary Analysis  
We also conducted a series of secondary analysis to ensure robustness of the association 
between TRD and economic outcomes.  First, we used inverse probability of treatment weighting 
(IPTW) to account for observable selection bias between TRD and no TRD groups. 112 IPTWs 
were derived from a multivariable logistic regression, in which presence or absence of TRD was 
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the dependent variable. Second, we assessed the association between TRD and total all-cause 
and MDD related healthcare costs over time. We captured costs during the observation period in 
120-day periods over six intervals.  In these models, polypharmacy (>5 concomitant use of 
medications in a period of 90 days), use of benzodiazepines and use of pain –related medications 
such as opioids and NSAIDs were measured in each of the 120-day periods. To account for 
correlated errors terms due to repeated measures, we used generalized linear mixed model 
(GLMM) with gamma distribution and log link.  
IPTW adjustments (Appendix 7.7) and GLMM yielded results similar to the primary 
analyses (Appendix 7.9). For example, GLMM analysis indicated that on average, patients who 
transitioned to TRD had significantly higher all-cause total costs ($1746.5; β = 0.31; P value 
<0.001) and MDD-related costs (β = 1.38; P value <0.001) at every time point in the baseline 
and follow-up periods even after adjusting for patient characteristics (Appendix 7.9). 
3.5 Discussion 
Approximately one in 10 adults with CNPC and newly diagnosed MDD were identified 
as having TRD, a finding consistent with some previously reported estimates of TRD from other 
claims-based studies (6% to 15%).22,29,44,46 We observed that patients with TRD had 
approximately 1.4 times higher total all-cause healthcare costs than adults without TRD. 
Although, to date, no study has estimated excess economic burden of TRD among adults with 
CNPC, we provide some comparisons based on studies that used similar algorithms to identify 
TRD among in adults with MDD. Our adjusted total cost was similar to the estimates provided 
by Gibson et al., who reported that TRD was associated with 40% higher total healthcare costs 
among adults with MDD. 23 The findings from the current study were robust to the different 
specifications of the models used in primary and sensitivity analysis. All models indicated 
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significantly higher costs among adults with TRD compared to no TRD group. We observed a 
higher economic burden among TRD patients at every 120-day period over two years.  A 
plausible reason may be the unremitting depressive state experienced by the TRD patients. Prior 
research suggests that TRD patients had persistent depressive symptoms for nearly 61% of the 
time over a three-year period.113   Therefore, our findings suggest that efforts in preventing 
transition from MDD to TRD by screening patients for risk factors of TRD such as presence of 
comorbid anxiety disorders, suicidal tendencies, hospitalization status, and high depression 
symptom severity26,27,29 can potentially reduce costs of MDD among adults with CNPC and 
newly diagnosed MDD. 
 In our study sample of adults with CNPC and newly diagnosed MDD, a significant 
portion of the total all-cause costs was accounted by prescription drug costs, a finding consistent 
with prior studies of TRD in commercially insured populations.22,42 We also observed that 
polypharmacy rates from our study were significantly higher in the TRD group as compared to 
no TRD group (69.4% vs 49.6%). Furthermore, results from the linear decomposition method 
indicated that polypharmacy was a major driver of the excess total costs associated with TRD. 
Our findings suggest that if adults with TRD were to have the same polypharmacy rates as adults 
without TRD, the excess total cost burden associated with TRD as explained by all the 
measurable baseline factors can be reduced by more than half (55.7%). Interventions that have 
shown to reduce the risk of polypharmacy such as systematic review of high risk medications 
(termed as "deprescribing"), medication therapy management, medication reconciliation, and 
using a multidisciplinary care approach114 have the potential to off-set the excess costs due to 
polypharmacy. Future studies on the cost of illness of TRD should use polypharmacy as a 
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measure for risk-adjustment while presenting adjusted incremental cost estimates associated with 
TRD.   
 Inpatient costs also accounted for a substantial share of all-cause as well as MDD-related 
total healthcare costs. This is consistent with reports obtained from previous studies conducted 
among adults with MDD. 22,25,42 The finding is also reflected by the significantly higher number 
of all-cause (IRR=1.30) as well as MDD-related inpatient visits (IRR=3.00) among adults with 
TRD as compared to those without TRD. A study by Crown et al. also reported that as compared 
to the TRD patients treated in outpatient care, hospitalized TRD patients had significantly higher 
MDD-related hospitalization as well as general medical costs.25Although, we did not explore the 
reasons for all-cause or MDD-related hospitalizations, adults with TRD may have higher risk of 
hospitalization and inpatient costs due to higher polypharmacy rates and greater occurrence of 
chronic conditions such as number of CNPC, anxiety and substance use disorders as observed in 
our study. It has been documented that polypharmacy can elevate risks of adverse drug–drug 
interactions, which can lead to increased rates of hospitalizations and inpatient costs.115 TRD 
patients may also engage in high-risk behavior such as substance use and suicidal attempts, at a 
higher rate than no TRD patients,116,117which are all factors that increases the risk of 
hospitalization and re-admissions.118,119 
  We also found that multimorbidity (example: number of CNPC, presence of anxiety, 
sleep and substance use disorders) to be one of the major drivers of the excess total costs 
associated with TRD.  Research has shown that multimorbidity has a profound impact on 
healthcare costs due to several reasons such as increased use of emergency department visits, 
adverse drug events due to polypharmacy, and complex disease trajectories due to interactions 
among chronic conditions.120 For example, adults with three or more CNPC may experience 
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severe pain that may worsen clinical outcomes among adults with TRD.7 Co-management of 
these commonly co-occurring conditions is often difficult, and results in higher healthcare 
costs.121 Therefore, our findings suggests that the complex needs of patients with multimorbidity 
can be better managed through healthcare delivery models that use collaborative and 
multidisciplinary approaches.  Such models have been shown to improve clinical outcomes, and 
reduce costs as compared to the usual source of care.122,123 124  
Strengths and Limitations 
To date, this is the first real-world study to quantify the direct economic burden of TRD 
among adults with CNPC and MDD; two very commonly co-occurring chronic conditions. The 
longitudinal study design with repeated measures allowed for an assessment of baseline as well 
as follow-up profiles in terms of utilization, expenditures as well as baseline patient 
characteristics. Further, MGH scoring algorithm to identify TRD allows for a nuanced and 
comprehensive assessment of TRD by accounting for number of failed adequate trials, treatment 
dose, titration, duration and augmentation. Additionally, the current study ensured robustness of 
study findings by adjusting for observed selection bias through IPTWs and by employing the use 
of counterfactual-recycled predictions in addition to the use of a two-part GLM model. This 
allowed us to obtain estimates for an average patient as compared to estimates obtained from a 
reference-case scenario using marginal effects derived from the two-part GLM regression 
models. 
Although the insights from the current study are important, the limitations of the current 
study need to be considered while interpreting the study findings. TRD was defined using 
pharmacy claims and ECT use and excludes other clinical considerations such as type of 
symptoms, responsiveness to medical treatments, and tolerance to antidepressants. Further, we 
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may not have truly captured the actual use of medication as we could observe only presence of 
prescription claims. It is also plausible that by limiting patients to only MDD diagnosis, we may 
have underestimated the prevalence of MDD because MDD may at times could be recorded with 
general depression code. As shown from the results of the decomposition analysis, absence of 
information on factors such as severity of MDD and pain, socioeconomic status, race/ethnicity, 
physical activity, and social support could contribute to the unexplained portion of the total costs 
differences between adults with and without TRD, which could impact the study findings. Our 
study estimated costs from a third-party payer perspective, therefore; indirect costs such as costs 
related to traveling, caregiving and loss of productivity have not been considered. In estimating 
costs associated with MDD, costs of prescription medications have not been considered as 
medications such as antidepressants and atypical antipsychotics were used in the algorithm to 
identify patients with TRD and these medications could also be used for other physical 
conditions such as pain, and insomnia. 125 Finally, although our study was not limited to 
including only working-aged adults, our results may not be generalizable to other privately and 
publicly insured adults. Additionally, no direct inference should be made about the prevalence of 
TRD based on the size of the analytical sample which was selected based on several 
inclusion/exclusion criteria. 
3.6 Conclusion 
This is the first study to document the excess direct economic burden of TRD among 
adults with CNPC and newly diagnosed MDD. TRD in adults with CNPC and newly diagnosed 
MDD was associated with substantial all-cause and MDD–related costs and HRU. Estimates 
from our study can provide a benchmark of TRD costs for future cost-effectiveness studies and 
in estimating risk-adjusted cost for value-based reimbursement initiatives. Potential cost savings 
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associated with managing TRD may stem from reducing the risk of polypharmacy, better co-
management of chronic pain and co-occurring substance use, anxiety, and sleep disorders.  
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Figure 3.1. Schematic presentation of study sample selection  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Patients with MDD in years 2008-2016 
N=683,701 
Patients who are cancer free and have >2 diagnosis of any 
CNPC in 12 months before MDD  
N=201,955 
) 
 
Patients without schizophrenia, schizoaffective disorders, 
other psychosis, manic depression or bipolar disorder 
N=192,328 
 
Patients with newly diagnosed MDD (No MDD diagnosis 
or antidepressant prescription in prior 180 days)  
N=90,937 
Patients receiving antidepressant treatment (>1 
antidepressant fill after MDD diagnosis) 
N=50,664 
Final analytical sample: Patients aged >18 years with 
continuous enrollment up to 24 months before and 12 
months after the TRD index date 
N=21,180 
Patients classified with 
TRD 
N=2,147 (10.1%) 
Patients not meeting the 
definition of TRD 
N=19,033 (89.9%) 
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Table 3.1. Baseline Characteristics of Adults with CNPC and Newly Diagnosed MDD 
 Optum Clinformatics Real-World De-identified Data, 2007-2017 
  
Overall (N=21,180) 
Patients classified 
with TRD 
(N=2,147) 
Patients without 
TRD (N=19,033) 
    
Characteristics N  %  N  %  N  % P value Sig 
 Predisposing factors  
Age, Mean (SD) 
55.18 (17.60) 53.25 (16.62) 55.84 (17.69) <0.001 *** 
Female 15,610 73.7 1,654 77.0 13,956 73.3 <0.001 *** 
Age group       <0.001 *** 
18-34 years 2,781 13.1 293 13.6 2,488 13.1 
 
  
35-44 years 3,119 14.7 360 16.8 2,759 14.5 
 
  
45-54 years 4,190 19.8 497 23.1 3,693 19.4 
 
  
55-64 years 4,087 19.3 448 20.9 3,639 19.1 
 
  
>65 years 7,003 33.1 549 25.6 6,454 33.9 
 
  
Enabling factors 
Medicare Advantage Enrollment     0.106   
Commercial 12,470 58.9 1,299 60.5 11,171 58.7 
 
  
Medicare Advantage 8,710 41.1 848 39.5 7,862 41.3 
 
  
Insurance plan type       0.269   
HMO 7,439 32.1 661 30.8 6,129 32.2 
 
  
PPO/POS 11,317 46.9 1,042 48.5 8,899 46.8 
 
  
Other 4,889 21.0 444 20.7 4,005 21.0 
 
  
Need Factors 
No. of CNPC a       <0.001 *** 
1 4,823 22.8 402 18.7 4,421 23.2    
2 9,430 44.5 873 40.7 8,557 45.0    
>3 6,927 32.7 872 40.6 6,055 31.8    
Number of physical chronic conditions b      0.893   
0 7,925 37.4 808 37.6 7,117 37.4    
1 to 2 7,620 36.0 777 36.2 6,843 36.0    
>3 5,635 26.6 562 26.2 5,073 26.7 
 
  
Anxiety disorders 8,057 38.0 1,195 55.7 6,862 36.1 <0.001 *** 
Sleep disorders 5,227 24.7 722 33.6 4,505 23.7 <0.001 *** 
Tobacco use disorders 2,428 11.5 320 14.9 2,108 11.1 <0.001 *** 
Drug/alcohol use disorder 1,892 8.9 342 15.9 1,550 8.1 <0.001 *** 
Obesity diagnosis 3,487 16.5 383 17.8 3,104 16.3 0.07   
Polypharmacy c       <0.001 
*** 
Yes 10,926 51.6 1,490 69.4 9,436 49.6    
No 10,254 48.4 657 30.6 9,597 50.4    
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Commonly used medications c          
NSAIDs 5,328 25.2 601 28.0 4,727 24.8 0.001 ** 
Opioids 7,285 34.4 792 36.9 6,493 34.1 0.01 * 
Benzodiazepines 6,542 30.9 928 43.2 5,614 29.5 <0.001 *** 
Environmental factor 
Census region of residence       5.23 0.156 
Northeast 1,910 9.0 217 10.1 1,693 8.9    
Midwest 5,154 24.3 535 24.9 4,619 24.3    
South 8,610 40.7 866 40.3 7,744 40.7    
West 5,506 26.0 529 24.6 4,977 26.1    
Bassline costs and resource use e 
Baseline visit to provider          
Primary Care provider 16,063 75.8 1,930 89.9 14,133 74.3 <0.001 *** 
Mental health specialist 4,872 23.0 1,046 48.7 3,826 20.1 <0.001 *** 
All-cause healthcare visits (>1)          
Inpatient  4,468 21.1 648 30.2 3,820 20.1 <0.001 *** 
ED 7,938 37.5 987 46.0 6,951 36.5 <0.001 *** 
Outpatient 15,637 73.8 1,702 79.3 13,935 73.2 <0.001 *** 
MDD- related healthcare visits (>1)         
Outpatient 1,443 6.8 318 14.8 78 5.9 <0.001 *** 
Inpatient  687 3.2 182 8.5 505 2.7 <0.001 *** 
ED 544 2.6 131 6.1 413 2.2 <0.001 *** 
All-cause healthcare costs (2018 US$), Mean (SD)        
Total costs 17,287 (42,843) 23,138 (39,632) 16,627 (43,141) <0.001 *** 
MDD-related healthcare costs (2018 US$), Mean (SD)        
Total MDD related medical 
costs 916 (7,079) 1,772 (8,125) 818 (6,944) <0.001 
*** 
Abbreviations: MDD: Major Depressive Disorder, TRD: Treatment- resistant depression, CNPC: Chronic non-cancer pain conditions, HMO: 
Health Maintenance Organization, PPO: Preferred provider organization, POS: Point of service, other plan type includes fee-for-service, 
indemnity plans, EPO (exclusive provider organization), GPO (Group purchasing organization), IPP(individual program plan), and other 
plans, NSAIDs: Non-steroidal anti-inflammatory drugs, SD: Standard deviation. ED: emergency department, Sig: Significance 
Note: Based on 21,180 adults with CNPC and newly diagnosed MDD receiving antidepressant medication treatment who were continuously 
enrolled during the observation period. All baseline factors were measured in the 12-month period before the index date. The first TRD date 
was used as the index date for patients classified as having TRD and for those classified as non-TRD patients, a pseudo index date was 
randomly selected based on the TRD index date. 
a Number of CNPC conditions were obtained as sum of common chronic painful conditions such as back/neck pain, headache/migraine, 
arthritis/joint pain, and neuropathic pain/other chronic pain conditions.                                                                                                                   
b Physical chronic conditions examined included conditions other than CNPC conditions such as asthma, coronary artery disease, cardiac 
arrhythmias, congestive heart failure, chronic kidney disease, chronic obstructive pulmonary disease, diabetes, hypertension, hyperlipidemia, 
osteoporosis, and stroke. 
c Polypharmacy was defined as concomitant use of five or more medications within a 90 day period before the index date. 
e Total all-cause healthcare costs included the standardized costs for all healthcare medical and pharmacy services paid by payers, including 
those for outpatient visits, inpatient stays, ED visits, and prescription medications. Total MDD-related medical costs included costs for 
medical- related services including inpatient visits, outpatient and ED visits. 
 
*** p < 0.001.; ** .001 ≤ p < .01; * .01 ≤ p < .05 
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Table 3.2. Mean Annual Adjusted and Unadjusted All-Cause and MDD-Related Costs  
Among Adults with CNPC and Newly Diagnosed MDD by TRD status 
Optum Clinformatics DataMart, 2007-2017 
  
Patients 
classified 
withTRD  
Patients 
without 
TRD 
Unadjusted 
Incremental costs 
Adjusted Incremental 
costs, Model 1 a 
Adjusted Incremental 
Costs,Model 2 b 
Outcomes Unadjusted 
Mean (SD), 
$ 
Unadjuste
d Mean  
(SD), $ 
Mean $ 
 (95% CI); P value 
Mean $ 
 (95% CI); P value 
Mean $ 
 (95% CI); P value 
All-cause healthcare costs (2018 US$) 
Total 21,015 
 (42,504) 
14,712  
(42,746) 
6303 
 (4,396 - 8,209); <0.001 
3,388 
(3,353-3,419); <0.001 
2,025 
(2,015 - 2,056); <0.001 
Prescription 
drug costs 
6,286 
 (10,014) 
3,913 
 (9,050) 
2373 
 (1,964 - 2,781); <0.001 
1,281 
(1,370-1,293); <0.001 
776 
(768 - 785); <0.001 
Inpatient 7,603 
 (34,608) 
5,667 
 (34,969) 
1,936  
(377 - 3,495); 0.014 
1,329 
(1,313 - 1,346); 0.012 
894 
(883 - 907); 0.108 
Outpatient 5,338  
(14,972) 
3,998  
(17,545) 
1,340 
(567 - 2,112) ;<0.001 
764 
(758 - 770); 0.008 
 662 
( 656 - 668); 0.004 
ED 1,789  
(5,100) 
1,135 
 (3,922) 
654 
 (473 - 835); <0.001 
223 
(221 - 225); 0.002 
174 
(172 - 175); 0.011 
MDD-related healthcare 
costs (2018 US$) 
   
  
Total  1,201 
 (5853) 
471 
 (3771) 
730  
(550 - 909); <0.001 
394 
(389 - 399); <0.001 
296 
(291 - 301); <0.001 
Inpatient 543  
(4557) 
169  
(2890) 
374  
(236 - 513); <0.001 
276 
(272 - 280); <0.001 
228 
(224 - 231); <0.001 
Outpatient 470  
(2,980)  
213  
(1,843) 
257 
 (168 - 346); <0.001 
84 
(92 - 85); <0.001 
61 
(60 - 62); <.001 
ED 188  
(1,178) 
89  
(869) 
99  
(57 - 138); <0.001 
14 
(13-15); 0.001 
12 
(11-13); 0.004 
Abbreviations: MDD: Major Depressive Disorder, TRD: Treatment- resistant depression, CNPC: Chronic non-cancer pain conditions, 
SD: Standard deviation; ED: Emergency Department 
Note: The sample includes all eligible adults with CNPC and newly diagnosed MDD who are treated with antidepressants and were 
continuously enrolled throughout the study observation period (N=21,180) from the de-identified Optum Clinformatics DataMart. 
All the costs were standardized to 2018 US dollar. Total all-cause healthcare costs included the standardized costs for all healthcare 
medical and pharmacy services paid by payers, including those for outpatient visits, inpatient stays, ED visits, and prescription 
medications. Total MDD-related medical costs included costs for medical- related services including inpatient visits, outpatient and ED 
visits. Total MDD-related costs were identified based on primary/secondary diagnoses of MDD.  
Unadjusted incremental costs and their corresponding P value and 95% CIs have been obtained using ordinary least square regressions. 
a  Incremental costs from Model 1 were measured using counterfactual recycled predictions performed using estimates obtained from a 
2-part GLM model with log link and gamma distribution which adjusted for baseline factors: predisposing factors (age, sex), enabling 
factors (Medicare Advantage enrollment, type of insurance plan), need based factors (number of physical chronic conditions, number of 
CNPC, presence of anxiety disorders, sleep disorders, obesity, and baseline medication use (polypharmacy, NSAIDs, opioid and 
benzodiazepine use), and environmental factors (region). 
b Incremental costs from Model 2 were measured using counterfactual recycled predictions performed using estimates obtained from a 2-
part GLM model with log link and gamma distribution which adjusted for all baseline factors mentioned in model 1 and healthcare costs. 
a,b All P values and their confidence intervals were obtained using nonparametric bootstrap procedure (N=500) on the predicted values 
obtained from recycled predictions. 
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Figure 3.2. Adjusted average annual healthcare resource utilization associated with TRD 
among adults with CNPC and newly diagnosed MDD 
 
Note: All healthcare resource utilization was measured from the index date up to 12 months after the index date. The sample 
includes all eligible adults with CNPC and newly diagnosed MDD who are treated with antidepressants and were continuously 
enrolled throughout the study observation period (N=21,180) from the de-identified Optum Clinformatics DataMart. 
Adjusted IRRs and their corresponding P values were obtained using a generalized linear model (GLM) with a negative binomial 
distribution (based on the results of the over dispersion test). The model adjusted for baseline predisposing factors (age, sex), 
enabling factors (Medicare Advantage enrollment, type of insurance plan), need based factors (number of physical chronic 
conditions, number of CNPC, presence of anxiety disorders, sleep disorders, obesity, and baseline medication use 
(polypharmacy, NSAIDs, opioid and benzodiazepine use), environmental factor (region), and baseline healthcare utilization.  
Abbreviations: MDD: Major Depressive Disorder, TRD: Treatment- resistant depression, CNPC: Chronic non-cancer pain 
conditions, SD: Standard deviation; ED: Emergency Department, IRR: Incidence Rate Ratio 
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Table 3.3. Post Linear Decomposition to Explain Contribution of Patient Factors on All-Cause Total 
Healthcare Cost: Differences by TRD Status  
Among Adults with CNPC and Newly Diagnosed MDD  
Optum Clinformatics DataMart, 2007-2017 
Explained Differences in Average Log-transformed All-Cause Total Healthcare Costs 
    Pooled 
 
  
Characteristics  
Explained 
(β) 
SE; P Value % 
difference d 
Predisposing factors      
  Age, Sex 0.0127 0.0045; 0.006 3.78% 
Enabling factors     
  Insurance plan type, Medicare Advantage Enrollment 0.0003 0.0033; 0.938 0.08% 
Need factors     
  No. of CNPC 
a 
 0.0377 0.0051; <0.001 11.24% 
  Anxiety disorders, sleep disorders 0.0274 0.0058; <0.001 8.17% 
  Tobacco use disorders. Drug/alcohol use disorder 0.0369 0.0052; <0.001 10.99% 
  
No. of physical chronic conditions b, Obesity diagnosis 
-0.0021 0.0074; 0.779 -0.63% 
  Polypharmacy  0.1870 0.0113; <0.001 55.73% 
  
Commonly used medications: NSAIDs use, Opioid 
use, Benzodiazepine use 0.0171 0.0045; <0.001 5.09% 
External environment     
  Region  0.02 0.0048; <0.001 5.53% 
  Total explained  0.34  46.02% 
Abbreviations: MDD: Major Depressive Disorder, TRD: Treatment- resistant depression, CNPC: Chronic non-cancer pain conditions, 
SE: Standard Error 
Note: The sample includes all eligible adults with CNPC and newly diagnosed MDD who are treated with antidepressants and were 
continuously enrolled throughout the study observation period (N=21,180) from the de-identified Optum Clinformatics DataMart. 
a Number of CNPC conditions were obtained as sum of common chronic painful conditions such as back/neck pain, 
headache/migraine, arthritis/joint pain, and neuropathic pain/other chronic pain conditions.                                                                                                                     
b Physical chronic conditions examined included conditions other than CNPC conditions such as asthma, coronary artery disease, 
cardiac arrhythmias, congestive heart failure, chronic kidney disease, chronic obstructive pulmonary disease, diabetes, hypertension, 
hyperlipidemia, osteoporosis, and stroke. 
c Polypharmacy was defined as concomitant use of five or more medications within a 90-day period before the index date. 
All the costs were standardized to 2018 US dollar. Total all-cause healthcare costs included the standardized costs for all healthcare 
medical and pharmacy services paid by payers, including those for outpatient visits, inpatient stays, ED visits, and prescription 
medications.  
The post linear decomposition is based on pooled weights. The pooled weights were derived from parameter estimates of ordinary least 
square regression (OLS).   
Average log-transformed total healthcare expenditures for adults with TRD was 8.93 and for adults without TRD was 8.20, yielding a 
difference of 0.73 
Column d gives the percentage of the difference in total all-cause expenditures by TRD as explained by differences in each independent 
variable domain between the two groups 
Explained portions of no. of physical health conditions/obesity diagnosis had negative signs. These negative signs suggest that keeping 
other factors constant, if the "TRD" group had the same distribution of characteristics as the "no TRD" group; no. of physical health 
conditions/obesity diagnosis), the all-cause total healthcare expenditures of individuals with TRD would be higher. 
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CHAPTER 4  
4 Trajectories of Long-term Opioid Use: The Role of Treatment-Resistant Depression 
among Adults with Chronic Non-Cancer Pain Conditions and Newly Diagnosed Major 
Depressive Disorder 
4.1 Abstract 
Background: Although treatment guidelines discourage long-term opioid therapy (LTOT) for 
patients with co-existing chronic non-cancer pain conditions (CNPC) and major depressive 
disorder (MDD), many patients receive LTOT in real–world practice settings. Further, treatment-
resistant depression (TRD) may increase the risk of LTOT. We examined the trajectory of LTOT 
use before and after MDD diagnosis and the association of TRD with LTOT among patients with 
CNPC and newly diagnosed MDD. 
Methods: Retrospective, longitudinal analysis of patients with CNPC and newly diagnosed 
MDD (N=21,599) using de-identified data from commercially insured adults (January 2007-June 
2017) was conducted. TRD was identified using a claims-based algorithm and LTOT (defined as 
>90 consecutive days) of prescription opioids was measured every 180 days over a 3-year period 
anchored to the date of MDD diagnosis. The adjusted relationship between TRD and LTOT was 
examined using generalized estimating equation models. 
Results: In our study sample, 11.8% of adults with CNPC transitioned from MDD to TRD. 
During the study period, LTOT use declined from 15.6% in time 1 to 10.3% in time 6 (P < .001). 
Adults identified with TRD were more likely to receive LTOT, as compared to those without 
TRD [adjusted odds ratio (AOR): 1.54, 95% CI: 1.68-2.04). However, LTOT in this group 
declined over time at a higher rate, than those without TRD (β= -.033, SE=0.012).  
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Conclusion: Adults with TRD were more likely to receive LTOT at every time period over a 3-
year period than those without TRD, although LTOT use declined over time. Close monitoring 
of the risks of using LTOT among adults with CNPC and TRD is warranted. 
4.2 Introduction 
Given that many patients with chronic non-cancer pain conditions CNPC suffer from 
persistent pain, they often receive long-term opioid therapy (LTOT),81,126 commonly defined as 
continuous use of opioid beyond 90 days. 126-128 Use of LTOT in patients with CNPC is 
controversial, 33,34,53,129-131 with some believing that it may improve pain outcomes,132 while 
others warning that the evidence is limited regarding the effectiveness of LTOT for different 
types of chronic pain  such as neuropathic, nociceptive, and mixed pain types.133,134 Furthermore, 
LTOT often increases the risk of adverse events such as constipation, nausea, addiction, and 
opioid-induced hyperalgesia.134,135 
In fact, clinical guidelines do not recommend use of LTOT among specific subgroups of 
patients, specifically those with co-occurring CNPC and major depressive disorder (MDD). 55 
Prevalence rates of MDD range from 28% in population-based research to as high as 89% in 
orthopedic clinics.17, 18 Prospective studies have reported that MDD makes chronic pain less 
responsive to opioids among adults with CNPC,55,136 further limiting the clinical benefits of 
LTOT in this subgroup. Despite lack of robust evidence on the long-term efficacy of opioids, 
many patients with CNPC and MDD receive LTOT in real-world practice settings. It has been 
reported that adults with MDD and CNPC are more likely to receive LTOT, as compared to 
those without MDD.56 Because pain is also a somatic symptom of depression, MDD can make 
chronic pain worse in adults with CNPC. This may lead to opioid prescribing at a much higher 
rate and longer duration among those with CNPC and MDD, than in patients who have CNPC 
  64 
without MDD.60,137,138 As MDD is harder to treat with antidepressants in the presence of chronic 
pain,11 LTOT may be prescribed at a higher rate for pain control to patients who do not respond 
to multiple antidepressant trials.55 Patients with MDD and co-occurring CNPC have a higher risk 
of developing treatment-resistant depression (TRD),20,22,24,29 commonly defined as failing 
multiple trials of antidepressants.17-20 TRD may increase the use of  LTOT55 as the neural 
patterns of activation that are associated with depression are also associated with pain, and 
LTOT may be prescribed to treat the complex combination of both pain and TRD.55,57 
On the other hand, clinicians may be cautious in prescribing LTOT to patients with MDD 
who develop TRD because these patients may also have higher rates of substance use disorders, 
including opioid-use disorders.55,139 Therefore, it is plausible that LTOT use before and after 
MDD diagnosis may vary, and TRD may alter this trajectory. To date, no study has examined the 
trajectory of LTOT among adults with CNPC and newly diagnosed MDD, or the association of 
TRD with LTOT. TRD is now receiving increased attention because of its high clinical, 
economic and societal burden.20  The only retrospective study in the US that examined the 
relationship between TRD and LTOT focused on Veterans, and reported that LTOT is a risk 
factor for TRD. The study did not report on the association of TRD with LTOT.30 
An understanding of the relationship between LTOT and TRD is important for several 
reasons. First, LTOT among adults with TRD may be deemed to be “high-risk” as both LTOT 
and TRD are independently associated with increased risk of substance use disorders,54,139 and 
adverse health outcomes20,22 Second, patients with TRD receiving LTOT comprise a patient 
population where the benefits of LTOT are questionable and vulnerability to risks of adverse 
events related to LTOT are very high; making it critical for healthcare providers to weigh the 
risks versus benefits of using LTOT in this group of patients. Furthermore, having an 
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understanding of LTOT prescribing patterns among individuals with CNPC and newly diagnosed 
MDD is important to better inform clinical practice, payers, and policy makers in their 
surveillance and prevention efforts of controlling opioid- related misuse and abuse. To fill the 
existing knowledge gap and provide further insights on the real-world pattern of LTOT use, the 
current study sought to examine the trajectory of LTOT over a 3-year period in adults with 
CNCP and the association of TRD with LTOT among adults with CNPC and newly diagnosed 
MDD.  
4.3 Methods 
Data Source 
 
The study used health claims from the de-identified 10% sample drawn from the Optum 
Clinformatics ® DataMart (Optum Clinformatics ®, Eden Prairie, MN, USA) 67  from 1st January 
2007 through 30th June 2017. This geographically diverse database contains information on 
prescription drug claims [e.g. generic drug names, days’ supply, prescription fill dates], medical 
claims (e.g. International Classification of Diseases, ninth/tenth revision [ICD-9/10] diagnoses, 
Current Procedural Terminology codes], and eligibility information [e.g. age, sex].67 
Study Design  
 
We adopted a retrospective, observational, longitudinal cohort design, with repeated 
measurements of LTOT every 180-days for six time points (T1, T2, T3, T4, T5, and T6) over a 
3-year observation period. Repeated measurements were anchored to the date of newly 
diagnosed MDD with pre-index (T1, T2) and post-index periods (T3, T4, T5, and T6).  To allow 
sufficient time for follow-up newly diagnosed MDD was restricted to the period between 
January 1, 2008 to June 30, 2015. To ensure that the episode of MDD was newly diagnosed 
episode, we used a validated algorithm of including only those who did not have any MDD 
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diagnosis or antidepressant prescription in 180 days prior to the MDD diagnosis date.78,79 A 12-
month pre-index period was used for cohort identification and TRD was identified in the 
subsequent 12-month post-index period (T4 and T5) (Figure 4.1). 
Study Cohort 
 
The study cohort comprised commercially insured adults with CNPC and newly 
diagnosed MDD identified using ICD-9 codes (see Appendix 7.1 for classification codes). Adults 
with CNPC were required to have at least two healthcare encounters during the pre-index period. 
Chronic non-cancer pain conditions, identified using an extensive list of conditions for which 
pain was severe enough to call them as chronic pain conditions,80-82 was grouped into four broad 
categories encompassing the most common pain conditions (back/neck pain, headache/migraine, 
arthritis/joint pain, neuropathic/other chronic pain).127,140 Other inclusion/exclusion criteria were 
age > 18 years, at least one prescription of antidepressant following MDD diagnosis, no cancer 
diagnosis, and continuous enrollment throughout the study observation period. Additionally, 
similar to prior studies we excluded patients with any diagnosis of schizophrenia, schizoaffective 
disorder, other psychosis, manic depression or bipolar disorders.22,23 After applying the 
inclusion/ exclusion criteria, the final study sample consisted of 21,599 adults (Figure 4.2). 
Measures 
Key Independent Variable: Treatment Resistant Depression  
 
Due to a lack of consensus on the definition of TRD, there are inconsistencies in the 
measures/algorithms used to identify TRD from a claims database.72,141,142 For the current study, 
adults with TRD were identified using a comprehensive claims-based staging algorithm that was 
developed using the General Hospital (MGH) clinical staging method. 23,61 As per this algorithm, 
a patient with CNPC and MDD was classified as meeting the criteria for TRD if his/her MGH 
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score exceeded three points. Patients were scored as follows: 1) one point was assigned for each 
adequate antidepressant trial (i.e., 2 or more fills of the same antidepressant); 2) half a point was 
assigned for each optimization strategy (included extended duration, i.e. at least 3 fills of the 
same antidepressant, an upward titration in dose, and augmentation with an atypical 
antipsychotic, mood stabilizer, thyroid hormone;233) Four points for patients using 
electroconvulsive therapy (i.e. those using ECT were directly considered to have TRD as ECT is 
often used for late-stage treatment for TRD.7(See Appendix 7.10 for the list of augmentation 
medications and the number of patients meeting each of the MGH scoring criteria).  
Outcome: Long-term opioid therapy (LTOT) 
 
Opioids were identified using the therapeutic drug classification for opiate agonists 
(codeine, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine, morphine, 
oxycodone, oxymorphone, and pentazocine) from the dataset.30  Following the algorithms used 
in published literature, LTOT was defined as receiving greater than 90 days’ supply of opioids 
with less than a 30-day gap between two fills within a 180-day period.30,127,128,140,143 A threshold 
of >90 days was chosen because it corresponds to usually 4 or more prescriptions and it is 
unlikely for an individual to receive opioids for >90 days for acute pain conditions. Additionally, 
this threshold represents an important point in the treatment process where clinicians would want 
to be cautious of the clinical risk of continuing opioid treatment, thereby making it a reasonable 
threshold for risk analysis.128,140 We explored the effect of TRD on LTOT using a sensitivity 
analysis by defining LTOT using a 120-day period of continuous opioid supply with a 30-day 
permissible gap.56 In the current study, we used LTOT as defined by duration of opioid use as 
our outcome variable and not dose of opioids because previous studies have highlighted that new 
onset of MDD and TRD is associated with longer duration of opioids and not dose.30,137,144 
Other Independent Variables 
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 Selection of other explanatory variables (time invariant and time-varying) was guided by the 
expanded Symptom Management Model.65,66 As per the proposed framework, presence of TRD, 
which is mainly non-response to antidepressant treatment trials, was considered as a symptom 
experience which can influence the outcome of LTOT. As per the model, the above dimensions 
can be influenced by the following three domains: (1) the personal domain, which comprised of 
demographic and socio-economic factors (e.g. age, sex, insurance plan type, Medicare advantage 
enrollment), (2) the health and illness domain (e.g. chronic physical conditions, obesity, sleep 
disorders, substance use disorders, polypharmacy, benzodiazepine use, and use of pain 
medication such as NSAIDs); (3) the environmental domain (e.g. geographical region, index 
year). Our study included both time varying and time invariant factors. Substance-use disorders, 
polypharmacy, NSAIDs and benzodiazepine use were measured during each time interval from 
T1 to T6. All other variables were measured during the baseline (pre-index period). 
Statistical Analyses 
 
 Differences in baseline sample characteristics among adults by LTOT status in the pre-
index period and TRD status in the post-index period (T4 and T5) were compared using chi-
square tests for categorical variables and t-tests for continuous variables (e.g. age). Considering 
that LTOT was measured repeatedly every 180-days during the pre- and post-index period, with 
each individual having six observations, these six observations were not independent. As 
standard regression techniques cannot be applied to correlated observations, we used unadjusted 
and adjusted generalized estimating equations (GEE).145 The GEE accounts for correlated error 
terms due to repeated measures from the same individual and is fairly robust to choice of 
correlation matrix, particularly with large sample sizes. In the current study, population-averaged 
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GEE with binary distribution was used. A population averaged model provides group effect, in 
contrast to subject-specific model which includes a ‘unique’ effect for each individual.146 
We also analyzed the interaction between TRD and time to elucidate the impact of TRD 
on the trajectory of use of LTOT over time. Unadjusted and adjusted Odds Ratios and their 
corresponding 95% confidence intervals have been reported. The adjusted GEE model controlled 
for time, personal, health and illness, and environmental factors. All data management and 
analyses were performed with SAS 9.4 (SAS Institute Inc., Cary, NC) and Stata 14 (StataCorp 
LLC, College Station, TX).  
4.4 Results 
Sample Characteristics 
Among 21,599 adults with CNPC and newly diagnosed MDD, 2550 (11.80%) met the 
criteria for TRD within one year of MDD diagnosis, with a mean time of 8 months. Adults with 
CNPC and newly diagnosed MDD were mostly females (73.6%) with a mean age of 55.2 years. 
The majority of adults in our study had arthritis/joint pain (91%), followed by back/neck pain 
(71%). About 16% of adults were on LTOT during the pre-index (baseline) period. (Table 4.1).  
Sample Characteristics by TRD 
 TRD patients were mostly younger with a mean age of 53.7 years, as compared to those 
without TRD (mean age=55.43 years). There were significant differences in personal factors and 
health and illness –related factors between adults with and without TRD. For example, a greater 
percentage of adults with TRD had >3 CNPC (41.4% vs. 32.2%), had co-existing sleep disorders 
(29.9% vs. 22.0%), anxiety disorders (36.9% vs. 26.5%), and used polypharmacy (59.1% vs. 
43.4%), as compared to CNPC patients without TRD (all P<.001) (Appendix 7.11). 
Sample Characteristics by use of LTOT 
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 The baseline sample characteristics among those using LTOT and not using LTOT in the 
pre-index period differed significantly across all domains, including personal, environmental, 
and health and illness factors (All P <0.01) (Table 4.1). For example, a higher percentage of 
adults on LTOT were males (28.3 % vs. 16.1%), had >3 CNPC (58.5% vs. 28.2%), and had >3 
physical chronic conditions (35.0% vs. 26.3%). 
Trajectory of LTOT over 3-year study period 
 In our sample, LTOT use declined from 15.7% in T1 to 10.3% in T6 and the decline was 
significant (Figure 4.3). In unadjusted GEE models, when time was included as the only 
covariate, the time co-efficient was found to be negative (  = -.055, SE=.003), suggesting that 
LTOT use decreased over time. For example, LTOT use was less likely at T6 (OR = 0.76, 95% 
CI= 0.73- 0.79), compared to the pre-index (T2) period (Table 4.2). When examined by TRD 
status, a significantly higher percentage of adults with TRD used LTOT (P < .001) as compared 
to non-TRD patients at all time-points (Figure 4.3). Those with TRD were more likely to receive 
LTOT (OR = 1.76; 95% CI = 1.62-1.91), after adjustment for time. Over time, the difference in 
LTOT rates among TRD and non-TRD patients narrowed (T1: 9.7 percentage point difference; 
T6: 5.0 percentage point difference). The interaction term between time and TRD status was 
negative (  -.022, SE= .01), suggesting that TRD patients had a greater decline in LTOT, 
compared to non-TRD patients (Table 4.2). 
In fully-adjusted models (after adjusting for TRD, time-interaction with TRD, personal, 
environmental, and health and illness factors), adults with TRD were 1.5 times as likely to use 
LTOT, as compared to adults without TRD (AOR=1.55, 95% CI=1.39-1.71, P value <0.001). 
The interaction term between time and TRD status remained negative (  -.033, SE=0.012) and 
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statistically significant (P Value = 0.006). The sensitivity analyses, where LTOT was defined as 
>120 days’ supply of opioids, showed similar results (Appendix 7.12 and 7.13). 
Other factors associated with LTOT included: male sex, younger age (35-64 years), 
greater number of CNPC and physical chronic health conditions, comorbid anxiety disorders, 
polypharmacy, any use of NSAIDs, and benzodiazepines (Table 4.2). Furthermore, adults 
diagnosed with MDD in years after 2010, had lower odds of LTOT use, as compared to those 
diagnosed in years 2008-2010 (years 2011-2013: AOR: 0.86, 95% CI: 0.79-0.94; years 2014-
2015: AOR: 0.66, 95% CI: 0.61-0.72).  
4.5 Discussion 
To the best of our knowledge, this is the first real-world study that examined the 
trajectory of LTOT among adults with CNPC and newly-diagnosed MDD, and the association of 
TRD with LTOT. We found an average LTOT rate of 16% , which is in line with a previous 
study that reported a prevalence of 12% to 30%  LTOT use among adults with CNPC and mood 
disorders.140 Overall, we found that adults who transitioned from MDD to TRD were 
significantly more likely to receive LTOT, as compared to adults who did not transition to TRD. 
This difference remained statistically significant at all time points. Even after adjusting for time 
and other patient factors, adults with TRD were more likely to receive LTOT (AOR=1.54, P 
value <0.001), compared to those without TRD.  Although it was not possible to ascertain 
reasons for higher LTOT use among TRD patients, there are some possible explanations based 
on what is known about TRD and chronic pain. It is well known that adults with TRD report 
greater severity of depression, physical symptoms, higher levels of pain, and a higher number of 
CNPC, as compared to those with MDD without TRD. 22,24,26 11,147 It is plausible that those with 
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TRD have more severe pain which may not be responsive to first line pain therapies and opioids 
may be prescribed to these patients to treat an undifferentiated state of mental and physical pain.  
While TRD is associated with LTOT, we cannot rule out the possibility that LTOT may 
worsen depression symptoms over time,55 which may lead to TRD.30 In fact, to date, only one 
retrospective cohort study in the United States (US) has reported increased risk of new onset 
TRD due to longer duration of opioid use among Veterans.30 A recent study has also reported 
that mu opioid receptor agonists may worsen depression symptoms thereby increasing the risk of 
TRD.30 On the other hand, emerging evidence from clinical trials suggests that antagonists of the 
kappa opioid receptor, such as buprenorphine, may improve depression symptoms, 148,149 
reducing the risk of TRD.149 Therefore, future real-world studies are needed to explore the 
bidirectional relationships between LTOT and TRD, and the role of antagonists of the kappa 
opioid receptors for managing both pain and TRD. 
 A noteworthy finding was the general decline in LTOT over the 3-year observation 
period among CNPC patients newly diagnosed with MDD in recent years. Additionally, adults 
diagnosed with MDD in recent years (2011-2015) were less likely to use LTOT, as compared to 
those diagnosed in years 2008-2010. We also observed a greater decline in LTOT use among 
patients with TRD, as compared to those without TRD. Although comparable study findings do 
not exist in the currently published literature, the discontinuation of LTOT over time has been 
documented to be more pronounced among patients with substance-use disorders who are 
deemed to be a high risk group.150 We speculate clinician initiated discontinuation may be higher 
among adults with TRD, as they are recognized as a high-risk group, given their greater severity 
of depression symptoms, higher risk of suicidal ideation and substance-use disorders55,56,138. 
Therefore clinicians may decide to taper the use of LTOT because of lack of pain relief, opioid-
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related side effects, and adverse events including opioid dependence and misuse. 151 Such trends 
are encouraging and may be due to increased attention to opioid abuse and awareness of their 
risks in the past few years.152   
 However, the consistently higher LTOT use among adults with TRD over all time 
periods suggests the need to closely monitor CNPC patients with MDD and TRD. Considering 
the lack of robust evidence on the effectiveness of opioids for CNPC,33,34,53,129-131 and clinical 
guidelines recommending against LTOT for chronic pain and MDD,55 future studies are needed 
to identify the reasons for high rates of LTOT among TRD patients. Providers may need to 
weigh the risks versus benefits of using LTOT in this patient population. 
Additionally, our results also indicated that patient-level risk factors for LTOT identified 
from our study, including male sex, age, higher number of CNPC, higher number of physical 
health conditions, presence of anxiety disorders and, benzodiazepine use have also been 
identified by other studies as risk factors for clinically recognized opioid dependence and abuse 
among adults with CNPC.55,128,153 Providers need to assess risk factors while deciding 
appropriate pain management strategies for patients with CNPC and MDD. Providing 
collaborative multidisciplinary care for patients with CNPC, MDD and other chronic conditions 
in an integrated setting (e.g. patient centered medical homes) can optimize interactions between 
primary care providers and mental health specialists, improving patient outcomes.154 155 
Additionally, behavioral interventions such as mindfulness-based or cognitive behavioral therapy 
can be effective alternative strategies to manage patients with co-occurring chronic pain, 
depression and other mental and physical health conditions.156 
4.6 Limitations 
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The study has several strengths, including availability of a large cohort of patients with 
CNPC and MDD treated for depression in a real-world setting, and utilized a longitudinal study 
design to track individuals over time, enabling assessment of temporal relationships. Our study 
used a comprehensive algorithm that encompasses the four main strategies to overcome lack of 
response, including optimization, switching, combination, and augmentation62,106 to identify 
adults with TRD. To ensure robustness of study findings, the current study also tested the impact 
of TRD on LTOT by varying the definitions of the study outcome. However, several limitations 
should also be noted. First, TRD exists along a clinical continuum and there is a lack of 
consensus on its definition. Although, the current study used a comprehensive claims-based 
algorithm to define TRD mainly through pharmacy claims, a study relying on claims-based 
information does not give comparable level of clinical information such as persistence of 
depression symptoms, and tolerance to antidepressants. Further, lack of information on severity 
of MDD, pain level, socio-economic status, and race/ethnicity may lead to unobserved selection 
bias. It is plausible that our algorithm for identifying newly diagnosed episode of MDD (a look-
back period of 180 days) may not truly capture all incident MDD patients. Furthermore, 
prescription drug claims provide information only on filled prescriptions and not actual use. 
Lastly, no direct inference should be made about the prevalence of TRD among adults with 
CNPC and newly diagnosed MDD, given the specific inclusion /exclusion criteria of the study. 
Although, our observed prevalence of 11.8% is consistent with some previously reported 
estimates of TRD among adults with MDD obtained from other claims-based studies (6% to 
15%).22,29,44,46 
4.7 Conclusion 
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The present study demonstrated that LTOT declined over time. Although the decline in 
LTOT was greater in patients with TRD, LTOT rates were consistently higher among TRD 
patients, as compared to those without TRD. Considering that patients with CNCP and MDD 
who transition into TRD and continue to use LTOT are a high-risk group with substantial disease 
burden, multidisciplinary and targeted behavioral approaches along with integrated care, may be 
needed to co-manage CNCP and MDD.   
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Figure 4.1. Schematic of the study design 
 
 
Each individual was observed for 36 months with a 12-month baseline period, (cohort identification period where 
adults with CNPC and newly diagnosed MDD were identified), 12- month TRD identification period and 12-month 
post TRD –identification period (follow-up periods). LTOT was measured repeatedly every 180 days during the 
baseline and follow-up periods, yielding a total of 6 repeated measures for each individual. 
 
Abbreviations: MDD; Major depressive disorder; CNPC: Chronic non-cancer pain conditions; TRD: Treatment-resistant 
depression; LTOT: Long-term opioid therapy 
 
Figure 4.2. Schematic presentation of study sample selection 
Attrition Flowchart  
Total cases of MDD from January 1, 2008 through December 31,2016 
(N=518,396) 
Patients who were cancer free and had >2 diagnosis of any CNPC in 12 months before 
MDD  
(N= 154,304) 
Patients without schizophrenia, schizoaffective disorders, other psychosis, 
manic depression or bipolar disorder 
(N= 147,403) 
Patients with newly diagnosed MDD (No MDD diagnosis or antidepressant 
prescription in prior 180 days) 
 (N=70,018) 
Patients receiving antidepressant treatment (>1 antidepressant fill after MDD 
diagnosis) 
(N=52,384) 
Final analytical sample: Patients aged >18 years with continuous enrollment 12 
months before and 24 months after the MDD diagnosis date (index date) 
(N=21,599) 
Patients classified with TRD = 2,550;  
Patients not meeting the definition of TRD = 19,049 
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Table 4.1. Overall Baseline Sample Characteristics and Characteristics by use of LTOT among Adults with 
CNPC and Newly Diagnosed MDD (measured during pre-index period) 
 Optum Clinformatics Real-World De-identified Data, 2007-2017 
  
Overall Sample 
(N=21,599) 
Use of LTOT 
(N=3,561) 
No use of LTOT 
(18,038)     
Characteristics N 
Percent 
(%)  N  
Percent 
(%)  N  
Percent 
(%) 
P 
value Sig 
 Personal factors  
Age, Mean (SD) 55.24 (17.51) 59.65 (14.30) 54.36 (17.94) <0.001 *** 
Female 15,902 73.6 2,553 71.7 13,349 83.9 0.004 ** 
Age group       <0.001 *** 
18-34 years 2,837 13.1 151 4.2 2,686 14.9    
35-44 years 3,342 15.5 381 10.7 2,961 16.4    
45-54 years 4,354 20.2 777 21.8 3,577 19.8    
55-64 years 4,112 19.0 933 26.2 3,179 17.6    
>65 years 6,954 32.2 1,319 37 5,635 31.2    
Medicare Advantage Enrollment     <0.001 *** 
Commercial 13,119 60.7 2,145 60.2 11,703 64.9    
Medicare Advantage 8,480 39.3 1,416 39.8 6,335 35.1    
Insurance plan type       <0.001 *** 
HMO 6,893 31.9 1,450 40.7 5,443 30.2    
PPO/POS 10,346 47.9 1,192 33.5 9,154 50.7    
Other 4,360 20.2 919 25.8 3,441 19.1    
Environmental factors 
Census region of residence      <0.001 *** 
Northeast 2,001 7.1 254 10.5 1,747 9.7    
Midwest 5,363 19.8 705 25.4 4,658 25.8    
South 8,684 45.5 1,621 39.3 7,063 39.2    
West 5,551 27.5 981 24.8 4,570 25.3    
Index Year 
Years 2008-2010 6,271 29 925 26.0 5,346 29.6 <0.001 *** 
Years 2011-2013 7,105 32.9 1,169 32.8 5,936 32.9    
Years 2014-2015 8,223 38.1 1,467 41.2 6,756 37.5    
Health and illness related factors 
Type of CNPC          
Back/Neck Pain (yes) 15,368 71.2 3,071 86.2 12,297 68.2 <0.001 *** 
Arthritis/Joint Pain(yes) 19,728 91.3 3,364 94.5 16,364 90.7 <0.001 *** 
Headache/Migraine (yes) 7,135 33 1,255 35.2 5,880 32.6 0.002 ** 
Neuropathic/other chronic pain 
(yes) 4,774 22.1 1,904 53.5 2,870 15.9 <0.001 *** 
No. of CNPC a       <0.001 *** 
1 4,813 22.3 287 8.1 4,526 25.1    
2 9,604 44.5 1,179 33.1 8,425 46.7    
>3 7,182 33.3 2,095 58.8 5,087 28.2    
Number of  physical chronic conditions b      <0.001 *** 
0 8,947 37.4 902 25.3 8,045 44.6    
1 to 2 7,566 36.0 1,446 40.6 6,120 33.9    
>3 5,086 26.6 1,213 34.1 3,873 21.5    
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Anxiety disorders(yes) 5,987 27.7 1,246 35.0 4,741 26.3 <0.001 *** 
Sleep disorders(yes) 4,957 23.0 1,073 30.1 3,884 21.5 <0.001 *** 
Substance use disorders (yes) 1,308 6.1 480 13.5 828 4.6 <0.001 *** 
Obesity diagnosis (yes) 3,366 15.6 713 20.0 2,653 14.7 <0.001 *** 
Polypharmacyc       <0.001 *** 
Yes 9,768 45.2 2,680 75.3 7,088 39.3    
No 11,831 54.8 1,043 40.9 10,788 56.6    
Commonly used medications c         
NSAIDS use 5,576 25.8 1,224 34.4 4,352 24.1 <0.001 *** 
Benzodiazepine use 6,039 28.0 1,562 43.9 4,477 24.8 <0.001 *** 
Abbreviations: MDD: Major Depressive Disorder, TRD: Treatment- resistant depression, CNPC: Chronic non-cancer pain 
conditions, HMO: Health Maintenance Organization, PPO: Preferred provider organization, POS: Point of service, other plan 
type includes fee-for-service, indemnity plans, EPO (exclusive provider organization), GPO (Group purchasing organization), 
IPP(individual program plan), and other plans, NSAID: Non-steroidal anti-inflammatory drugs, SD: Standard deviation, Sig: 
Significance 
Note: Based on 21,599  adults with CNPC and newly diagnosed MDD receiving antidepressant medication treatment who 
were continuously enrolled during the observation period. LTOT as well as all baseline sample characteristics factors were 
measured during the pre-index period (t2). 
Long-term opioid therapy (LTOT) was defined  as at least a > 90 days of continuous supply of prescription opioids within a 
180 day period 
a Number of CNPC conditions were obtained as sum of common chronic painful conditions such as back/neck pain, 
headache/migraine, arthritis/joint pain, and neuropathic pain/other chronic pain conditions.                                                                                                                   
b Physical chronic conditions examined included conditions other than CNPC conditions such as asthma, coronary artery 
disease, cardiac arrhythmias, congestive heart failure, chronic kidney disease, chronic obstructive pulmonary disease, diabetes, 
hypertension, hyperlipidemia, osteoporosis, and stroke. 
c Polypharmacy was defined as concomitant use of five or more medications within a 90 day period before the index date. 
***    p < 0.001.;  ** .001 ≤ p < .01; * .01 ≤ p < .05 
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Figure 4.3. Percentage of LTOT use over time for all adults and by TRD status among 
adults with CNPC and newly diagnosed MDD 
 
  
 
 
Abbreviations: MDD: Major Depressive Disorder, TRD: Treatment- resistant depression, CNPC: Chronic non-cancer pain 
conditions, LTOT: Long-term opioid therapy 
LTOT was defined as at least a > 90 days of continuous supply of prescription opioids within a 180-day period. 
P values for percentage of LTOT use over time for all adults, adults with TRD and without TRD were <0.001 
P values were obtained from unadjusted Generalized estimating equation models. 
 
 
 
 
 
 
 
 
 
 
Pre-Index Post-Index 
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Table 4.2: Unadjusted and Adjusted Odds Ratio and 95% Confidence Interval 
from Generalized Estimating Equation (GEE) of TRD on Long -term opioid 
therapy among 
Adults with CNPC and Newly Diagnosed MDD 
Optum Clinformatics Real-World De-identified Data, 2007-2017 
Characteristics Parameter 
estimate (β) 
SE OR 95 % CI P 
Value 
Model 1: Unadjusted association between time and LTOT 
Time -0.055 0.003 
  
<0.001 
Model 2: Unadjusted Association of time and TRD with LTOT 
TRD (Ref: No TRD) 
  Yes  0.56 0.043 1.76 [1.62, 1.91] <0.001 
Time -0.056 0.003 - - 
 
Model 2: Unadjusted Association of time, TRD, and interaction of time and TRD 
with LTOT 
TRD (Ref: No TRD) 
  Yes  0.62 0.050 1.85 [1.68, 2.04] <0.001 
Time -0.052 0.004 - - <0.001 
TRD*Time -0.022 0.020 - - 0.037 
Model 3: Adjusting for personal, environmental and health/illness related 
factors a 
Characteristics Parameter 
estimate (β) 
SE AOR 95 % CI P 
Value 
TRD (Ref: No TRD) 
  Yes  0.44 0.050 1.55 [1.39, 1.71] <0.001 
Time -0.048 0.004 - - <0.001 
TRD*Time -0.033 0.012 - - 0.006 
Age Group (Ref :>65 years) 
  18-34 years -0.18 0.179 0.86 [0.72, 1.02] 0.102 
  35-44 years 0.92 0.146 1.51 [1.31, 1.73] <0.001 
  45-54 years 1.49 0.123 1.87 [1.66, 2.10] <0.001 
  55-64 years 1.68 0.109 2.03 [1.84, 2.25] <0.001 
Sex (Ref: male) 
     
  Female -0.72 0.078 0.74 [0.69, 0.80] <0.001 
Index Year (Ref: Years 2008-2010)    
 Years 2011-2013 -0.32 0.087 0.86 [0.79-0.94] <0.001 
 Years 2014-2015 -0.85 0.090 0.66 [0.61-0.72] <0.001 
No. of CNPCb (Ref: 1 CNPC) 
  
  2 1.30 0.108 1.85 [1.65, 2.07] <0.001 
  >3 3.25 0.112 4.20 [3.75, 4.69] <0.001 
Number of physical chronic conditions c (Ref: 0) 
  1 to 2 0.28 0.088 1.25 [1.14, 1.36] <0.001 
  >3 0.17 0.104 1.21 [1.09, 1.34] <0.001 
Anxiety disorders (Ref No) 
    
  Yes  0.22 0.075 1.12 [1.04, 1.20] 0.001 
Sleep disorder (Ref: No) 
    
  Yes  0.25 0.078 1.08 [1.01, 1.17] 0.025 
Polypharmacy (Ref: No) 
    
  Yes  1.90 0.051 1.82 [1.75, 1.90] <0.001 
NSAIDs Use (Ref: No) 
    
  Yes  0.36 0.039 1.12 [1.08, 1.16] <0.001 
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Benzodiazepine use (Ref: no) 
    
  Yes  1.00 0.044 1.44 [1.38, 1.49] <0.001 
Abbreviations: MDD: Major Depressive Disorder, TRD: Treatment- resistant depression, 
CNPC: Chronic non-cancer pain conditions, NSAID: Non-steroidal anti-inflammatory drugs, 
OR: Odds ratio, AOR: Adjusted odds ratio, CI: Confidence Interval 
Note: Based on 21,599 adults with CNPC and newly diagnosed MDD receiving antidepressant 
medication treatment who were continuously enrolled during the observation period.  
Long-term opiod therapy was defined as at least a > 90 days of continuous supply of 
prescription opioids within a 180-day period 
a Only selected statistically variables are presented. The fully adjusted model adjusted for all 
personal factors (age, sex, insurance plan type, Medicare Advantage Enrollment), 
environmental factors (region of residence, index year), and health and illness factors (number 
of physical chronic conditions, number of CNPC, presence of anxiety disorders, sleep 
disorders, obesity, and medication use (polypharmacy, NSAID, and benzodiazepine use). 
Polypharmacy, NSAIDs and benzodiazepines used as time varying variables and were 
measured at all six time points.  
b Number of CNPC conditions were obtained as sum of common chronic painful conditions 
such as back/neck pain, headache/migraine, arthritis/joint pain, and neuropathic pain/other 
chronic pain conditions.                                                                                                                   
c Physical chronic conditions examined included conditions other than CNPC conditions such 
as asthma, coronary artery disease, cardiac arrhythmias, congestive heart failure, chronic 
kidney disease, chronic obstructive pulmonary disease, diabetes, hypertension, hyperlipidemia, 
osteoporosis, and stroke. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  82 
 
CHAPTER 5 
5 Summary and Conclusion 
5.1 Summary of Findings and Discussion 
Treatment-resistant depression, commonly defined as insufficient response to multiple 
antidepressant trials and augmentation strategies, 17-20 remains highly prevalent and exacts a 
substantial clinical, economic, and humanistic burden among adults with MDD.20 Managing 
TRD in patients with CNPC and MDD is even more challenging because of the complex bi-
directional relationship between depression and pain, which often exacerbates one another, and 
reduces benefits of depression and pain treatment.14,11,15 Existing literature on TRD has focused 
on all adults with MDD. Owing to the lack of research on TRD among adults with CNPC and 
MDD, we conducted this study to fill a critical knowledge gap and inform early interventions for 
reducing the risk of transitioning to TRD.  
Given that MDD and CNPC are both very costly conditions,8,11,157  and the presence of 
TRD can further amplify this economic burden, it is important to estimate the incremental 
economic burden associated with TRD. Estimating excess healthcare cost associated with TRD 
can establish benchmarks for future cost of illness and cost-effectiveness studies, and can help in 
translating the burden of illness into dollar terms, the universal language for healthcare decision 
making.49 Many healthcare policy initiatives have shifted focus to the pursuit of triple aim of 
improving health outcomes, quality of care and reducing healthcare costs. 48 This requires 
identification of not only high-cost but also high-risk and high-need patients. Despite 
recommendations against long-term opioid use among adults with CNPC and depression, LTOT 
continues to be prescribed to adults with CNPC and MDD in real-world. 56,60,137,138 LTOT use 
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among adults with TRD may make them a high-risk, high-need group as both LTOT and TRD 
are independently associated with high risk of substance-use disorders, including abuse and 
misuse of opioids, suicidal ideation and risk of hospitalizations. 20,22,54,139 Therefore, examining 
the trajectory of LTOT among patients with CNPC and newly diagnosed MDD, and the 
association of TRD with LTOT can inform clinical practice, payers, and policy makers in their 
surveillance efforts of controlling opioid- related misuse and abuse in these patients. 
Therefore, this dissertation pursued the following three related aims: 1) identifying 
leading predictors of TRD among adults with CNPC and newly diagnosed MDD; 2) estimating 
the direct economic burden associated with TRD and identifying factors that contribute to the 
excess cost burden of TRD; and 3) examining the trajectory of LTOT use in adults with CNPC 
and newly diagnosed MDD and how TRD can alter this trajectory. The current study, which 
focuses on predictors and outcomes associated with TRD among patients with CNPC and MDD 
is timely considering recent advances in the development of treatment options for TRD. After a 
period in which it seemed that the innovation of antidepressants with new mechanisms of action 
was going dry, the past decade has witnessed a renewed interest starting with the discovery of 
antidepressant properties of ketamine and other newer investigational antidepressants.158  The 
current study further highlights that there remains an unmet need for adequate treatment options 
to manage chronic pain and TRD, and suggests that patient with TRD and CNPC have a 
significant illness burden.  
Leading Predictors of TRD among adults with CNPC and newly diagnosed MDD 
We found that one in every nine adults with CNPC and newly diagnosed MDD 
transitioned to TRD within one year of MDD diagnosis. As demonstrated in this study, a smaller 
set of more easily assessed factors during the time of MDD diagnosis can be used to gauge the 
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risk of transitioning to TRD. The leading predictors identified using robust machine learning 
approaches included mental health specialist visits, use of psychotherapy after MDD diagnosis, 
polypharmacy, age, presence of comorbid anxiety disorders, use of benzodiazepines, inpatient 
status, index antidepressant class, and number of CNPC conditions. These factors may serve as 
targets of further investigation or clinical intervention to improve treatment outcomes in this 
population 
Impact of TRD on direct economic burden 
 Adults with CNPC who transitioned from MDD to TRD had significantly higher direct 
all-cause and MDD-related costs and healthcare resource utilization. Use of inpatient services 
and prescription drug costs accounted for a significant portion of the total all-cause costs. It is 
intuitive that adults with TRD will have higher prescription drug costs because of failure to 
respond to multiple trials of antidepressants, higher illness burden due to the presence of other 
chronic conditions, and higher use of polypharmacy. Our findings indicate that interventions 
focused on reducing the risk of transitioning to TRD may have the potential to prevent inpatient 
hospitalizations and can lead to cost savings for payers.  
Factors contributing to the excess cost burden of TRD 
Our findings indicated that 46% of the excess total costs among adults with TRD were 
explained by differences in patient level characteristics such as polypharmacy, number of CNPC, 
anxiety disorders, sleep disorders, and substance use disorders between the TRD and no TRD 
groups. Therefore, potential cost savings associated with managing TRD may stem from 
reducing the risk of polypharmacy, better co-management of chronic pain and co-occurring 
substance use, anxiety, and sleep disorders.  
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Trajectory of LTOT among adults with CNPC and MDD and association of TRD with 
LTOT 
 Patients with TRD were significantly more likely to receive LTOT as compared to adults 
with CNPC and MDD who did not meet the criteria for TRD at all time points during the 3 year 
study period. The reasons for the higher use of LTOT among adults with TRD are not clear. 
Future research needs to explore the reasons as to why TRD patients were more likely to receive 
LTOT despite treatment guidelines recommending against the use of LTOT in subgroup of 
adults with CNPC and MDD. Additionally, these findings further reinforce the need for specific 
clinical guidelines for pain management with opioids among adults with CNPC and MDD who 
meet the criteria for TRD and suggest that clinicians need to closely monitor the risks of using 
LTOT in this subgroup.  
 On the other hand, we observed that LTOT use declined at a higher rate among adults 
with TRD as compared to those without TRD in our study sample. These findings are 
encouraging and suggest that clinicians may decide to taper and discontinue the use of LTOT 
among adults with TRD perhaps due to lack of pain relief, higher risk of opioid –related side 
effects and adverse events such as risk of addiction, opioid dependence and misuse.  
5.2 Implications and Suggestions for Future Research 
Our study findings suggest that an individual’s transition from MDD to TRD among 
patients with CNPC can be predicted by information readily available in clinical settings such as 
presence of comorbid anxiety disorders, history of inpatient hospitalization, younger age, 
presence of higher number of CNPC, and indications of higher severity of MDD such as use of 
psychotherapy, and mental health specialist visits. The study findings provide some actionable 
evidence that can be utilized in real-world treatment decisions. For example, when a patient with 
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CNPC and newly diagnosed MDD first visits a healthcare provider, the presence of these 
characteristics may alert him/her to the possibility that the patient could develop TRD. 
Monitoring patients with these characteristics more closely, using targeted individualized 
treatment approaches, and using approaches such as augmentation strategies earlier in the 
treatment process may reduce the risk of TRD. There is a need to shift the focus of care from 
disease-specific to patient-centered care. The current study also highlights a huge unmet need for 
management of TRD among patients with CNPC and MDD. As the focus on developing newer 
treatment approaches for TRD is increasing in the past few years, 158 there is a need for studies 
examining the efficacy and effectiveness of these medications on not only alleviating depression 
symptoms but also pain symptoms. As MDD and chronic pain have overlapping neurobiological 
pathways, they often respond to similar treatments and therefore, effectively managing one 
symptom may also affect the other symptom. 14,15 Another important research implication is to 
test the validity of the leading predictors obtained from the current study using other datasets. 
Future studies also need to include a more comprehensive set of clinical variables that could not 
be examined in the current study, including, levels of inflammatory cytokines, pain scores, and 
psychological stress to identify predictors of TRD among patients with CNPC. 
 The current study is also the first study of its kind to estimate the direct economic burden 
associated with TRD among adults with CNPC and MDD. Therefore, quantification of the 
excess cost burden of TRD helps in translating the burden of illness into dollar terms which can 
be used as input parameters for future cost-effectiveness studies. Our findings can also inform 
payers and other stake-holders. As there is an emerging trend to focus on “value-based” care, 
which emphasize on quality care at lower costs, alternative payment models such as bundled 
payments, accountable care organizations, and medical homes are now increasingly used. As 
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bundled payment models require risk adjustment to account for differences in beneficiary-case 
mix,159 our findings suggest that an up to date estimate of economic burden for adults with MDD 
should also include excess costs due to TRD. As TRD is associated with a significantly high 
economic burden among patients with CNPC and MDD, our findings suggest that resource 
allocation for MDD-related expenditures should be higher for patients with TRD. 
The current study also highlights the patient level differences between adults with and 
without TRD that contribute to the excess cost burden of TRD using post-decomposition 
techniques. Our results suggest that the excess cost burden associated with TRD could be 
reduced by adequately managing polypharmacy, chronic pain, comorbid sleep, anxiety and 
substance-use disorders. Our findings suggest that interventions that have shown to reduce the 
risk of polypharmacy such as systematic review of high risk medications, medication therapy 
management, medication reconciliation, and using a multidisciplinary care approach114 have the 
potential to off-set the excess costs due to polypharmacy. Furthermore, existing research shows 
that the complex need of patients with multiple chronic conditions can be better managed 
through healthcare delivery models using multidisciplinary and collaborative care approaches. 
122,123 124Therefore, patient-centered care by integrating mental and physical health in primary 
care settings could improve treatment outcomes and potentially reduce costs associated with 
TRD. 
Our findings also provide clinical and policy implications regarding use of LTOT among 
patients with CNPC and newly diagnosed MDD. Consistently higher LTOT use among adults 
with TRD across all time periods suggests the need for providers to closely monitor patients for 
the risk of opioid related side-effects and adverse events such as opioid misuse, abuse and 
dependence. Providers may need to weigh the risks versus benefits of using LTOT in this patient 
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population. Real-world findings on patterns of LTOT use among patients with CNPC and MDD 
can further aid clinicians and policy makers in their surveillance efforts of combating the current 
opioid crisis. Despite the increased rate of LTOT use among patients with CNPC and MDD, data 
are lacking on the efficacy and safety of LTOT for CNPC, and particularly for patients with 
MDD or substance abuse who are generally excluded from randomized trials.33 Additionally, 
lack of data on efficacy and effectiveness of LTOT among adults with CNPC and TRD warrants 
well-designed pragmatic trials to provide evidence on the effectiveness of LTOT use. There is 
also a need for evidence-based clinical guidelines for use of LTOT in vulnerable groups such as 
adults with CNPC and TRD. Our study findings also highlight the need for future studies to 
ascertain clinical and patient-related reasons for high rates of LTOT use among patients with 
TRD. Given, that a study by Scherrer et al. has reported that LTOT is a risk factor for TRD,30and 
our study observed association of TRD with LTOT, future real-world studies are needed to 
explore the bidirectional relationships between LTOT and TRD. 
5.3 Strengths and Limitations  
The study has several strengths, including availability of a large cohort of patients with 
CNPC and MDD treated for depression in a real-world setting, and longitudinal study design to 
track individuals over time, thereby enabling assessment of temporal relationships. Our study 
used a comprehensive algorithm that encompasses the four main strategies to overcome lack of 
response, including optimization, switching, combination, and augmentation62,106  to identify 
adults with TRD. Additionally, the current study ensured robustness of study findings by 
conducting sensitivity analyses, adjusting for observed selection bias through IPTWs, and using 
advanced statistical techniques such as counterfactual-recycled predictions , two-part GLM 
model, generalized estimating equations, and machine learning using random forest. The use of 
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standardized prices for medical services, which adjusts for changes in payments based on local 
factors, such as labor costs allowed for more accurate comparisons of spending on healthcare 
services.160  
Our study findings should be interpreted in the context of some limitations. First, the 
study suffers from inherent limitations associated with claims data analysis, including coding 
inaccuracies, absence of information on the severity of MDD, socioeconomic status, 
race/ethnicity, physical activity, and social support. Second, TRD was defined using pharmacy 
claims and ECT use and excludes other clinical considerations such as type of symptoms, 
responsiveness to medical treatments, and tolerance to antidepressants which may under-estimate 
or over-estimate the prevalence of TRD. Third, we may not have truly captured the actual use of 
medication, as we could observe only presence of prescription claims. It is also plausible that by 
limiting patients to only MDD diagnosis, we may have underestimated the prevalence of MDD 
because MDD may at times could also be recorded using a general depression code. Finally, 
although our study was not limited to including only working-aged adults, our results may not be 
generalizable to other privately and publicly insured adults.  
5.5 Conclusion 
Overall, we identified that mental health specialist visits, polypharmacy (>5 
medications), psychotherapy use, presence of comorbid anxiety disorders, and age were the five 
leading predictors of TRD. TRD is associated with a high direct economic burden in terms of all-
cause and MDD-related costs and utilization among adults with CNPC and newly diagnosed 
MDD. Additionally, we observed that LTOT rates were consistently higher among TRD patients 
as compared to those without TRD across all time points; although the decline in LTOT was 
greater in patients with TRD as compared to those without TRD. Although this study fills a 
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critical knowledge gap, future research needs to confirm our study findings by including MDD 
severity, pain scores, level of inflammatory biomarkers, social support, and other unobserved 
factors such as income level, education, race and ethnicity that may affect the relationship 
between TRD and economic and clinical outcomes. Future studies also need to incorporate these 
factors when examining the risk factors of TRD among adults with CNPC and MDD.  Our 
findings suggest that use of multidisciplinary, collaborative, and targeted behavioral approach is 
needed to not only better manage patients with CNPC and TRD who use LTOT but also to better 
manage multimorbidity, polypharmacy, and to reduce the risk of inpatient hospitalizations. These 
approaches can also have the potential to reduce the excess costs associated with TRD. 
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Appendix 7.1. ICD-9/10 diagnosis codes used to identify CNPC, MDD and other chronic 
conditions 
  
Condition ICD-9 code set used ICD-10 code set used 
 
Major Depressive 
Disorders 
296.2x - dysthymic disorder (major 
depressive disorder-single episode) 
296.3x- dysthymic disorder (major 
depressive disorder, recurrent 
episode) 
309.0x - prolonged depressive 
reaction 
309.1x - prolonged depressive 
reaction 
300.4x- Adjustment disorder with 
depressed mood 
311.xx - depressive disorder, not 
elsewhere classified 
 
 
F320 - Major depressive disorder, single 
episode, mild 
F321 - Major depressive disorder, single 
episode, moderate 
F322 - Major depressv disord, single epsd, 
sev w/o psych features 
F323 - Major depressv disord, single epsd, 
severe w psych features 
F324 - Major depressv disorder, single 
episode, in partial remission 
F325 - Major depressive disorder, single 
episode, in full remission 
F328- Other depressive episodes 
F3289 - Other specified depressive episodes 
F329   -Major depressive disorder, single 
episode, unspecified 
F330 - Major depressive disorder, recurrent, 
mild 
F331 -Major depressive disorder, recurrent, 
moderate 
F332 - Major depressive disorder, recurrent 
severe w/o psych features 
F333 - Major depressive disorder, recurrent, 
severe w psych symptoms 
F3340- Major depressive disorder, recurrent, 
in remission, unspecified 
F3341 - Major depressive disorder, 
recurrent, in partial remission 
F3342 -Major depressive disorder, recurrent, 
in full remission 
F338 - Other recurrent depressive disorders 
F339 - Major depressive disorder, recurrent, 
unspecified 
F341 - persistent depression 
F432 – Stress induced depression  
schizophrenia, 
schizoaffective, 
other psychotic 
disorders related to 
schizophrenia, 
manic depression 
or bipolar disorders 
293.81, 293.82, 295,296.0, 296.1, 
296.4, 296.5, 296.6, 296.7, 296.8, 
296.9, 298 
F20, F06.0, F06.2, F25, F21, F22, F23, F24, 
F25.0, F25.1, F25.8, F28, F29, F31, 
Back/neck pain 720.0, 721.3x – 721.9x, 722.2x, 
722.30, 722.70, 722.80, 722.90, 
722.32, 722.72, 722.82, 722.92, 
M45.9, M46.1, M49.80, M40, M46.90 
M47, M48, M50.20, M50.30, M51 
M50.00, M96.1, M961, M46.4, M50.80 
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722.33, 722.73, 722.83, 722.93, 
724.xx, 737.1, 737.3, 738.4, 738.5, 
739.2, 739.3, 739.4, 756.10, 756.11, 
756.12, 756. 13, 756.19, 805.4, 
805.8, 839.2, 839.42, 846, 846.0, 
847.1, 847.3, 847.2, 847.9 
721.0x, 721.1x, 722.0x, 722.31, 
722.71, 722.81, 722.91, 723.XX, 
839.0, 839.1, 847. 0 
 
M50.90, M46.45, M48.02 M54.2, M53.0, 
M53.1, M54.12, M54.13 M43.6, M54.02, 
M67.88, M53.82, M48.00, M4804, M48.06 
M48.08, M54.6, M54.5, M54.30, M54.14 
M54.15, M54.16, M54.17, M54.89, M54.9 
M43.2, M53.2, M53.3, M54.08, M43.8X9 
M53.9, M96.2, M96.4Q7649, 
Q76.2, Q76.49, Q76.419, Q76.49, S32009A 
S12.9XXA, S32.009A, S32.10XA, 
S32.2XXA 
S338.XXA, S33.6XXA, S33.9XXA, 
S13.4XXA 
S13.8XXA, S23.3XXA, S23.3XXA, 
S23.8XXA 
S33.5XXA, S33.8XXA, S33.8XXA, 
S23.9XXA 
Headache/migraine 339.05,339.09, 339.10, 339.11, 
339.12, 339.20, 339.3, 339.41, 
339.42,339.43,339.44,339.81, 
339.82, 339.83, 339.84, 339.85, 
339.89, >346 and <347, 
784.0,307.81 
 
G44.85, G44.89, G43.109, G43.119, 
G43.101 
G43.111, G43.009, G43.019, G43.001, 
G43.011, 
G43.809, G43.A0, G43.B0, G43.C0, 
G43.D0, 
G43.819, G43.A1, G43.B1, G43.C1, 
G43.D1, 
G43.801, G43.811, G43.409, G43.419, 
G43.401 
G43.411, G43.829, G43.839, G43.821, 
G43.831, G43.509, G43.519, G43.501 
G43.511, G43.709, G43.719, G43.701 
G43.711, G43.809, G43.819, G43.801 
G43.811, G43.909, G43.919, G43.901, 
G43.911, 
G44.1, R51, G44.209 
 
Arthritis/joint pain 710, 711,713, 714, 715, 716, 717, 
718,719,725, 726, 727,728,729,730-
739 
 
M32.10, M34.0, M341, M34.9, M35.0 
M35.01, M00.10, M00-M02 
M36.2, M36.3, M12.2, M12.3, M12.4, 
M12.80, M12.80, M05, 
M06, M08, M12.0, M33.20, M45, M48.8, 
M15, M16, M17,M18 , M19, M12.1, 
M12.1,M12.8, M12.9, M13.0,M13.1, 
M13.8,M23.2, M23.3,M23.4, M23.5, M23.6, 
M23.8,M23.9, M24,M43.4, M25, 
M79.64,R29.89, R29.4, R26.2, M35.3, 
M65,M61, M62, M63, M66, M67, M70-
M79,M85, M86,M87,  M88.9, M89.00, 
M899, M89.6, M89.7, M90-M93,M94.0, 
M94.9 
Neuropathic 
pain/other chronic 
pain 
357, 337.0, 356.0, 356.2, 356.4, 
356.9, 357.2, 357.3, 531.3, 723.4, 
727.2, 338 
G60, G61.9, G61.0, G81.8, G62.0, G62.2, 
G63, E08.42, E09.42, E10.42, G89 
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Appendix 7.2. Chapter 2. Study design for predicting treatment resistant depression among 
adults with CNPC and newly diagnosed MDD  
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Appendix 7.3. Chapter 2. Representation of development and testing of machine learning 
model 
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Appendix 7.4. Chapter 2. Components of the Algorithm for identification of patients with TRD 
 
Component of TRD algorithm and the assigned score N Frequency  
At least 1 adequate trial of antidepressants, i.e. > 2 fills of same 
antidepressant medication (1 point) 
19,740 83.48% 
At least one extended duration, i.e. at least 3 fills of each antidepressant 
medication (0.5 point) 
17,557 74.25% 
Upward titration in dose (0.5 point) 5,537 23.42% 
Augmentation with atypical antipsychotics/mood stabilizer/thyroid hormone 
(0.5 point for each augmentation strategy) 
782 3.31% 
-Augmentation with atypical antipsychotics^ 645 2.73% 
-With mood stabilizers (carbamazepine, lamotrigine, lithium, valproic acid) 181 0.77% 
-With thyroid hormone (liothyronine) 21 0.09% 
ECT use -considered directly as having TRD (4 points) 11 0.005% 
TRD (> 3 points) 2,684 11.35% 
No TRD 20,961 88.65% 
Note: Based on 23,645 adults with CNPC and newly diagnosed episode of MDD using antidepressant 
medications, with continuous enrollment for 2 years in a commercial insurance plan. Individual 
components of TRD criteria will not add to 11.35% because an individual may satisfy one component of 
the algorithm while failing to satisfy another component of the algorithm.  
^ Medication names included in the class of atypical antipsychotics include aripiprazole, asenapine 
maleate, brexpiprazole, cariprazine, clozapine, lurasidone, olanzapine, paliperidone, paliperidone 
palmitate, quetiapine fumarate, risperidone, risperidone microspheres, and ziprasidone 
 
 
 
Appendix 7.5. Chapter 2. Performance measures for the prediction models 
Model AUC Sensitivity Specificity Out of bag error 
Training set      
Logistic Regression     
Fully adjusted model (n=40) 0.711 0.482 0.811 N/A 
Top 20 features 0.704 0.48 0.799 N/A 
Random forest      
Fully adjusted model (n=40) 0.716 0.52 0.9 11.42% 
Top 20 features 0.7 0.4 1 11.51% 
Testing set     
Logistic Regression     
Fully adjusted model (n=40) 0.708 0.576 0.801 N/A 
Top 20 features 0.705 0.572 0.8 N/A 
Random forest      
Fully adjusted model (n=40) 0.704 0.48 0.99 11.47% 
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Top 20 features 0.701 0.41 0.99 11.41% 
 
 
 
Appendix 7.6. Chapter 3. Baseline patient characteristics of adults with CNPC and Newly 
Diagnosed MDD by TRD status before and after Inversed Probability of Treatment 
Weighting (IPTW), Optum Clinformatics DataMart, 2007-2017 
    Patients 
classified 
with TRD 
(N=2,147) 
Patients 
without 
TRD 
(N=19,033) 
  
Patients 
classified 
with 
TRD 
(N=2,143) 
Patients 
without 
TRD 
(N=19,034) 
  
    %  % P value  Wt. % Wt.  % P value 
Characteristics        
Index Year   <0.001 
  
0.870 
  2008-2010 23.1 23.3 
 
23.4 23.3   
  2011-2013 38.7 33.3 
 
34.3 33.8   
  2014-2016 38.1 43.5 
 
42.3 42.9   
  
 
     
  
 Predisposing factors  
Sex   <0.001 
  
0.705 
  Female 77.0 73.3  74.1 73.7   
Age group   <0.001   0.732 
  18-34 years 13.6 13.1  12.7 13.1   
  35-44 years 16.8 14.5  14.3 14.7   
  45-54 years 23.1 19.4  19.7 19.8   
  55-64 years 20.9 19.1  18.8 19.3   
  >65 years 25.6 33.9  34.5 33.1   
Enabling factors 
Medicare Advantage   0.106 
  
0.366 
  Commercial 60.5 58.7 
 
57.8 58.9   
  Medicare 
Advantage 39.5 41.3 
 
42.2 41.1   
Insurance plan type  0.269 
  
0.742 
  HMO 30.8 32.2 
 
32.9 32.1   
  PPO/POS 48.5 46.8 
 
46.2 46.9   
  Other 20.7 21.0 
 
20.9 21.0   
Need factors  
No. of CNPC a   <0.001 
  
0.844 
  1 18.7 23.2 
 
23.2 22.8   
  2 40.7 45.0 
 
43.9 44.5   
  >3 40.6 31.8 
 
32.9 32.7   
Number of physical chronic conditions b 0.893 
  
0.112 
  0 37.6 37.4 
 
36.6 37.4   
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  1 to 2 36.2 36.0 
 
34.7 36.0   
  >3 26.2 26.7 
 
28.6 26.5   
Anxiety disorders   <0.001 
  
0.527 
  Yes 55.7 36.1 
 
38.8 38.1   
  No 44.3 63.9 
 
61.2 61.9   
Sleep disorders 
  
<0.001 
  
0.970 
  Yes 33.6 23.7 
 
24.6 24.7   
  No 66.4 76.3 
 
75.4 75.3   
Obesity diagnosis 
  
0.070 
  
0.860 
  Yes 17.8 16.3 
 
16.3 16.5   
  No 82.2 83.7 
 
83.7 83.5   
Tobacco use disorders 
 
<0.001 
  
0.910 
  Yes 14.9 11.1 
 
11.4 11.5   
  No 85.1 88.9 
 
88.6 88.5   
Drug/alcohol use disorder 
 
<0.001 
  
0.830 
  Yes 15.9 8.1 
 
8.8 8.9   
  No 84.1 91.9 
 
91.2 91.1   
Environmental factors 
Census region of residence  0.156   0.870 
  Northeast 10.1 8.9  9.6 9.0   
  Midwest 24.9 24.3  24.0 24.3   
  South 40.3 40.7  40.4 40.6   
  West 24.6 26.1   26.0 26.0   
Abbreviations: MDD: Major Depressive Disorder, TRD: Treatment- resistant depression, CNPC: Chronic 
non-cancer pain conditions, HMO: Health Maintenance Organization, PPO: Preferred provider organization, 
POS: Point of service, other plan type includes fee-for-service, indemnity plans, EPO (exclusive provider 
organization), GPO (Group purchasing organization), IPP(individual program plan), and other plans, Wt.: 
Weighted 
Note: This sample includes adult patients with CNPC and newly diagnosed MDD who were continuously 
enrolled in the medical and pharmacy obtained from the de-identified Optum Clinformatics DataMart. IPTW 
weights were derived from a multivariate logistic regression on TRD status using the above predisposing, 
enabling, need and environmental factors 
a Number of CNPC conditions were obtained as sum of common chronic painful conditions such as back/neck 
pain, headache/migraine, arthritis/joint pain, and neuropathic pain/other chronic pain conditions.                                                                                                                    
b Physical chronic conditions examined included conditions other than CNPC conditions such as asthma, 
coronary artery disease, cardiac arrhythmias, congestive heart failure, chronic kidney disease, chronic 
obstructive pulmonary disease, diabetes, hypertension, hyperlipidemia, osteoporosis, and stroke. 
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Appendix 7.7. Chapter 3. Mean Annual IPTW Adjusted and Unadjusted All-Cause and MDD-Related Costs Among 
Adults with CNPC and Newly Diagnosed MDD  
Optum Clinformatics DataMart, 2007-2017 
  
Patients 
classified with 
TRD  
Patients 
without TRD 
Adjusted Incremental costs, 
Model 1 a 
Adjusted Incremental 
Costs, Model 2 b 
Outcomes 
Unadjusted 
Mean (SD), $ 
Unadjusted 
Mean (SD), $ 
Mean $ 
 (95% CI); P value 
Mean $ 
 (95% CI); P value 
All-cause healthcare costs (2018 US$) 
Total 19,670 
(41,965) 
14,886  
(42,737) 
3,471 
(3,436-3,504); <0.001 
2,039 
2,017 - 2,058); <0.001 
Prescription drug 
costs 
5,909 
(9,281) 
3,953 
 (9,067) 
1,362 
(1,350-1,375); <0.001 
773 
(765 - 782); <0.001 
Inpatient 7,285 
 (34,122) 
5,720 
 (34,896) 
1,240 
(1,226 - 1,256); 0.011 
903 
(892 - 915); 0.148 
Outpatient 5,024 
(16,815) 
4,046 
(17,504) 
764 
(758 - 770); 0.008 
 637 
( 637 - 643); 0.012 
ED 1,454 
(4,237) 
1,169 
 (4,036) 
231 
(229 - 232); 0.002 
192 
(190 - 193); 0.011 
MDD-related healthcare costs (2018 
US$) 
  
  
Total medical costs 1,009 
 (5,067) 
480 
 (3,774) 
392 
(387 - 397); <0.001 
298 
(293 - 303); <0.001 
Inpatient 434 
(3,842) 
172 
(2,880) 
267 
(263 - 271); <0.001 
224 
(220 - 228); <0.001 
Outpatient 413  
(2,610)  
216 
(1,855) 
97 
(95 - 99); <0.001 
69 
(68 - 71); <.001 
ED 162  
(1,075) 
91 
(873) 
14 
(13-15); 0.002 
12 
(11-13); 0.005 
Abbreviations: MDD: Major Depressive Disorder, TRD: Treatment- resistant depression, CNPC: Chronic non-cancer pain conditions, 
SD: Standard deviation; ED: Emergency Department 
Note: The sample includes all eligible adults with CNPC and newly diagnosed MDD who are treated with antidepressants and were 
continuously enrolled throughout the study observation period (N=21,180) from the de-identified Optum Clinformatics DataMart. 
All the costs were standardized to 2018 US dollar. Total all-cause healthcare costs included the standardized costs for all healthcare 
medical and pharmacy services paid by payers, including those for outpatient visits, inpatient stays, ED visits, and prescription 
medications. Total MDD-related medical costs included costs for medical- related services including inpatient visits, outpatient and ED 
visits. Total MDD-related costs were identified based on primary/secondary diagnoses of MDD.  
Individual weights based on inverse probability of treatment weighting (IPTW) have been used for these analyses. 
Unadjusted incremental costs and their corresponding P value and 95% CIs have been obtained using ordinary least square regressions. 
a  Incremental costs from Model 1 were measured using counterfactual recycled predictions performed using estimates obtained from a 2-
part GLM model with log link and gamma distribution which adjusted for baseline factors: predisposing factors (age, sex), enabling 
factors (Medicare Advantage enrollment, type of insurance plan), need based factors (number of physical chronic conditions, number of 
CNPC, presence of anxiety disorders, sleep disorders, obesity, and baseline medication use (polypharmacy, NSAID, opioid and 
benzodiazepine use), and environmental factors (region). 
b Incremental costs from Model 2 were measured using counterfactual recycled predictions performed using estimates obtained from a 2-
part GLM model with log link and gamma distribution which adjusted for all baseline factors mentioned in model 1 and healthcare costs. 
a,b All P values and their confidence intervals were obtained using nonparametric bootstrap procedure (N=500) on the predicted values 
obtained from recycled predictions. 
 
  109 
  
Appendix 7.8. Chapter 3. Mean Annual Adjusted and Unadjusted All-Cause and MDD-Related 
Utilization Among Adults with CNPC and Newly Diagnosed MDD Treated with Antidepressants by TRD 
status 
Optum Clinformatics DataMart, 2007-2017 
  
Patients classified with 
TRD  
Patients without TRD  
  
Healthcare 
resource 
utilization 
N  
(% with >1 
visit) 
Mean (number 
of visits), (SD) 
N  
(% with >1 
visit) 
Mean 
(number of 
visits), (SD) 
Adjusted IRR a 
(95% CI) ; P value 
All-cause           
Inpatient  480 (22.4%) 0.47 (1.28) 3,023 (15.9%) 0.30 (0.97) 1.30 
(1.14 - 1.47) ; <0.001 
Outpatient  1,636 (76.2) 8.04 (15.80) 12,953 (68.1%) 6.72 (16.82) 1.24 
(1.15 - 1.34) ; <0.001 
ED 857 (39.9%) 1.06 (2.40) 5,859 (30.8%) 0.71 (1.94) 1.21 
(1.10 - 1.34) ; <0.001 
MDD-related           
Inpatient  77 (3.6%) 0.05(0.26) 198 (1.0%) 0.01 (0.12) 3.00 
(2.15 - 4.18) ; <0.001 
Outpatient  167 (7.8%) 3.86 (6.88) 625(3.3%) 2.41 (4.53) 2.95 
(2.03 - 4.29); <0.001 
ED 49 (2.3%) 0.03 (0.23) 154 (0.8%) 0.01 (0.13) 2.23  
(1.52 - 3.29) ; <0.001 
Abbreviations: MDD: Major Depressive Disorder, TRD: Treatment- resistant depression, CNPC: Chronic non-cancer pain conditions, 
SD: Standard deviation; ED: Emergency Department; CI: Confidence Interval; IRR: Incidence rate ratio 
Note: The sample includes all eligible adults with CNPC and newly diagnosed MDD who are treated with antidepressants and were 
continuously enrolled throughout the study observation period (N=21,180) from the de-identified Optum Clinformatics DataMart. 
MDD-related costs were identified based on primary/secondary diagnoses of MDD.  
a Adjusted IRRs and their corresponding 95% CIs and P values were obtained using a generalized linear model (GLM) with a negative 
binomial distribution (based on the results of the over-dispersion test). The model adjusted for baseline predisposing factors (age, sex), 
enabling factors (Medicare Advantage enrollment, type of insurance plan), need based factors (number of physical chronic conditions, 
number of CNPC, presence of anxiety disorders, sleep disorders, obesity, and baseline medication use (polypharmacy, NSAID, opioid 
and benzodiazepine use), environmental factor (region), and baseline healthcare utilization. 
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Appendix 7.9. Chapter 3. Unadjusted and Adjusted All-Cause Total and MDD-related Total Costs Over 
Time Among Adults with CNPC and Newly Diagnosed MDD Treated with Antidepressants by TRD status 
Optum Clinformatics DataMart, 2007-2017 
 
Costs/ 
time 
Patients classified 
with TRD  
Patients without 
TRD  
Unadjusted weighted 
cost difference 
between TRD and 
non-TRD groups a   
Adjusted weighted cost 
difference between TRD 
and non-TRD groups b    
Mean $ SD $ Mean $ SD $   
All-cause total healthcare costs (2018 
US$) 
  
β (time)= - 0.023;  
P Value <0.001        
β (TRD)= 0.35;  
P Value <0.001 
β (time)= - 0.017;  
P Value =0.005          
β (TRD)= 0.31;  
P Value <0.001 
Time 1 8,268.9 20,831.6 5,195.9 18,404.8 2389.33 1976.19 
Time 2  6,876.9 15,536.1 5,195.7 17,152.4 2282.78 1881.69 
Time 3 7,967.2 18,791.7 6,191.7 27,304.4 2180.22 1789.21 
Time 4 7,122.5 15,316.3 5,074.2 26,925.9 2081.52 1698.7 
Time 5 6,998.8 21,185.4 4,654.0 17,284.4 1986.54 1610.12 
Time 6 6,808.9 18,199.2 4,914.9 17,037.6 1895.15 1523.45 
      
Average difference = 
2135.92 
Average difference = 
1746.56 
MDD -related total medical costs (2018 
US$) 
  
β (time)= - 0.12;  
P Value =0.007        
β (TRD)= 1.37; 
 P Value <0.001 
β (time)= - 0.052;  
P Value =0.188        
β (TRD)= 1.38;  
P Value <0.001 
Time 1 538.5 5,787.4 83.0 3,548.9 436.16 449.51 
Time 2  339.6 3,484.5 95.3 1,657.5 335.34 365.81 
Time 3 524.0 3,347.7 254.3 4,956.6 256.49 294.51 
Time 4 348.4 3,944.7 87.7 2,051.8 194.97 218.63 
Time 5 199.8 1,757.0 67.2 1,784.9 147.09 162.36 
Time 6 168.1 1,783.6 63.2 1,287.7 109.95 120.97 
          
Average difference = 
246.67 
Average difference = 
268.63 
Abbreviations: MDD: Major Depressive Disorder, TRD: Treatment- resistant depression, CNPC: Chronic non-cancer pain conditions, SD: 
Standard deviation; 
Note: The sample includes all eligible adults with CNPC and newly diagnosed MDD who are treated with antidepressants and were 
continuously enrolled throughout the study observation period (N=21,180) from the de-identified Optum Clinformatics DataMart. 
All the costs were standardized to 2018 US dollar. Total all-cause healthcare costs included the standardized costs for all healthcare medical 
and pharmacy services paid by payers, including those for outpatient visits, inpatient stays, ED visits, and prescription medications. Total 
MDD-related medical costs included costs for medical- related services including inpatient visits, outpatient and ED visits. Total MDD-
related costs were identified based on primary/secondary diagnoses of MDD.  
a Unadjusted weighted incremental costs were obtained using counterfactual recycled predictions performed using estimates from 
Generalized Linear Mixed Models (GLMM) with log link and gamma distribution.  
b Adjusted weighted incremental costs were obtained using counterfactual recycled predictions performed using estimates from Generalized 
Linear Mixed Models (GLMM) with log link and gamma distribution. which adjusted for time invariant factors including predisposing 
factors (age, sex), enabling factors (Medicare Advantage enrollment, type of insurance plan), need based factors (number of physical 
chronic conditions, number of CNPC, presence of anxiety disorders, sleep disorders, obesity), environmental factors (region) and time 
varying factors including polypharmacy, NSAIDs, opioid and benzodiazepine use 
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Appendix 7.10. Chapter 4. Components of the Algorithm for identification of patients with TRD  
Component of TRD algorithm and the assigned score N Frequency  
(%) 
At least 1 adequate trial of antidepressants, i.e. > 2 fills of same antidepressant medication (1 
point) 
18,248 
 
84.48% 
At least one extended duration, i.e. at least 3 fills of each antidepressant medication (0.5 
point) 
16,341 
 
75.65% 
Upward titration in dose (0.5 point) 5,124 23.72% 
Augmentation with atypical antipsychotics/mood stabilizer/thyroid hormone (0.5 point for 
each augmentation strategy) 
-Augmentation with atypical antipsychotic^ 
-With mood stabilizers (carbamazepine, lamotrigine, lithium, valproic acid) 
-With thyroid hormone (liothyronine) 
732 
 
606 
166 
20 
3.39% 
 
2.81% 
0.77% 
0.09% 
ECT use -considered directly as having TRD  11 0.0005% 
TRD (> 3 points) 2,550 11.80% 
No TRD 19,049 88.20% 
Note: Based on 21,599 adults with CNPC and newly diagnosed episode of MDD treated with antidepressants and are continuously enrolled 
during the study observation period in a commercial insurance plan. Individual components of TRD criteria will not add to 11.35% because 
an individual may satisfy one component of the algorithm while failing to satisfy another component of the algorithm.  
^ Medication names included in the class of atypical antipsychotics include aripiprazole, asenapine maleate, brexpiprazole, cariprazine, 
clozapine, lurasidone, olanzapine, paliperidone, paliperidone palmitate, quetiapine fumarate, risperidone, risperidone microspheres, and 
ziprasidone 
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Appendix 7.11. Chapter 4. Sample Characteristics by TRD Status among Adults 
with CNPC and Newly Diagnosed MDD  
 Optum Clinformatics Real-World De-identified Data, 2007-2017 
  
Patients 
classified with 
TRD (N=2,550) 
Patients without 
TRD (N=19,049) 
    
Characteristics  N  
Percent 
(%) 
 N  
Percent 
(%) 
P 
value 
Sig 
 Personal factors  
Age, Mean (SD) 53.75 (16.71) 55.43 (17.60) <0.001 *** 
Female 1,941 76.1 13,961 73.3 0.002 ** 
Age group     <0.001 *** 
18-34 years 328 12.9 2,509 13.2 
 
  
35-44 years 446 17.5 2,896 15.2 
 
  
45-54 years 568 22.3 3,786 19.9 
 
  
55-64 years 536 21.0 3,576 18.8 
 
  
>65 years 672 26.4 6,282 33.0 
 
  
Medicare Advantage Enrollment    0.661   
Commercial 1,559 61.1 11,560 60.7 
 
  
Medicare Advantage 991 38.9 7,489 39.3 
 
  
Insurance plan type     0.598   
HMO 792 31.1 6,101 32.0 
 
  
PPO/POS 1,241 48.7 9,105 47.8 
 
  
Other 517 20.3 3,843 20.2 
 
  
Environmental factor             
Census region of residence    0.084   
Northeast 268 10.5 1,733 9.1    
Midwest 647 25.4 4,716 24.8    
South 1,002 39.3 7,682 40.3    
West 633 24.8 4,918 25.8    
Index Year 
Years 2008-2010 750 29.4 5,521 29 0.740   
Years 2011-2013 847 33.2 6,258 32.9    
Years 2014-2015 953 37.4 7,270 38.2     
Health and illness related factors 
Type of CNPC        
Back/Neck Pain (yes) 1,933 75.8 13,435 70.5 <0.001 *** 
Arthritis/Joint Pain(yes) 2,353 92.3 17,375 91.2 0.073   
Headache/Migraine (yes) 991 38.9 6,144 32.3 <0.001 *** 
Neuropathic/other 
chronic pain (yes) 701 27.5 4,073 21.4 <0.001 
*** 
No. of CNPC a     <0.001 *** 
1 453 17.8 4,360 22.9    
2 1,042 40.9 8,562 44.9    
  113 
>3 1,055 41.4 6,127 32.2    
Number of physical chronic conditions b   0.380   
0 1,028 40.3 7,919 41.6    
1 to 2 898 35.2 6,668 35.0    
>3 624 24.5 4,462 23.4 
 
  
Anxiety disorders(yes) 940 36.9 5,047 26.5 <0.001 *** 
Sleep disorders(yes) 763 29.9 4,194 22.0 <0.001 *** 
Obesity diagnosis (yes) 430 16.9 2,936 15.4 0.058   
Polypharmacy c     <0.001 
*** 
Yes 1,507 59.1 8,261 43.4    
No 1,043 40.9 10,788 56.6    
Commonly used medications c       
NSAIDS use 717 28.1 4,859 25.5 0.005 ** 
Benzodiazepine use 961 37.7 5,078 26.7 <0.001 *** 
Abbreviations: MDD: Major Depressive Disorder, TRD: Treatment- resistant depression, CNPC: 
Chronic non-cancer pain conditions, HMO: Health Maintenance Organization, PPO: Preferred 
provider organization, POS: Point of service, other plan type includes fee-for-service, indemnity 
plans, EPO (exclusive provider organization), GPO (Group purchasing organization), 
IPP(individual program plan), and other plans, NSAID: Non-steroidal anti-inflammatory drugs, 
SD: Standard deviation, Sig: Significance 
Note: Based on 21,599  adults with CNPC and newly diagnosed MDD receiving antidepressant 
medication treatment who were continuously enrolled during the observation period. All baseline 
factors were measured in the 12-month period before the index date. The first TRD date was used 
as the index date for patients classified as having TRD and for those classified as non-TRD 
patients, a pseudo index date was randomly selected based on the TRD index date. 
a Number of CNPC conditions were obtained as sum of common chronic painful conditions such 
as back/neck pain, headache/migraine, arthritis/joint pain, and neuropathic pain/other chronic 
pain conditions.                                                                                                                            b 
Physical chronic conditions examined included conditions other than CNPC conditions such as 
asthma, coronary artery disease, cardiac arrhythmias, congestive heart failure, chronic kidney 
disease, chronic obstructive pulmonary disease, diabetes, hypertension, hyperlipidemia, 
osteoporosis, and stroke. 
c Polypharmacy was defined as concomitant use of five or more medications within a 90 day 
period before the index date. 
***  <  p < 0.001;  ** .001 ≤ p < .01; * .01 ≤ p < .05 
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Appendix 7.12. Chapter 4. Percentage of LTOT use (defined as continuous opioid supply 
for >120 days) over time for all adults and by TRD status among adults with CNPC and 
newly diagnosed MDD 
 
Abbreviations: MDD: Major Depressive Disorder, TRD: Treatment- resistant depression, CNPC: Chronic non-cancer pain 
conditions, LTOT: Long-term opioid therapy. 
LTOT was defined as at least a > 90 days of continuous supply of prescription opioids within a 180-day period. 
P value for percentage of LTOT use over time for all adults, adults with TRD and without TRD was <0.001 
P-values were obtained from unadjusted Generalized estimating equation models. 
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Appendix 7.13. Chapter4. Unadjusted and Adjusted Odds Ratio and 95% Confidence 
Interval from Generalized Estimating Equation (GEE) of TRD on Long -term opioid 
therapy (defined as continuous opioid supply for >120 days) among 
Adults with CNPC and Newly Diagnosed MDD 
Optum Clinformatics Real-World De-identified  Data, 2007-2017 
Characteristics Parameter 
estimate (β) 
SE OR 95 % CI P Value 
Model 1: Unadjusted association between time and LTOT 
Time -0.056 0.003 - - <0.001 
Model 2: Unadjusted Association of time and TRD with LTOT 
TRD (Ref: No TRD) 
     
  Yes  0.56 0.045 1.75 [1.60, 1.91] <0.001 
Time -0.057 0.004 - - 
 
Model 2: Unadjusted Association of time, TRD, and interaction of time and TRD with 
LTOT 
TRD (Ref: No TRD) 
     
  Yes  0.63 0.052 1.87 [1.68, 2.07] <0.001 
Time -0.052 0.004 - - <0.001 
TRD*Time -0.029 0.011 - - 0.011 
Model 3: Adjusting for personal, environmental and health/illness related factors a 
Characteristics     AOR 95 % CI P Value 
TRD (Ref: No TRD) 
     
  Yes  0.45 0.055 1.57 [1.41, 1.75] <0.001 
Time -0.049 0.004 - - <0.001 
TRD*Time -0.041 0.013 - - 0.001 
Abbreviations: MDD: Major Depressive Disorder, TRD: Treatment- resistant depression, CNPC: Chronic 
non-cancer pain conditions, NSAID: Non-steroidal anti-inflammatory drugs, OR: Odds ratio, AOR: 
Adjusted odds ratio, CI: Confidence Interval 
Note: Based on 21,599 adults with CNPC and newly diagnosed MDD receiving antidepressant medication 
treatment who were continuously enrolled during the observation period.  
Long-term opioid therapy was defined as at least a > 120 days of continuous supply of prescription opioids 
within a 180-day period 
a Only selected significant variables are presented. The fully adjusted model adjusted for all personal 
factors (age, sex, insurance plan type, Medicare Advantage Enrollment), environmental factors (region of 
residence, index year), and health and illness factors (number of physical chronic conditions, number of 
CNPC, presence of anxiety disorders, sleep disorders, obesity, and medication use (polypharmacy, 
NSAID, and benzodiazepine use). Polypharmacy, NSAIDs and benzodiazepines used as time varying 
variables and were measured at all six time points.  
b Number of CNPC conditions were obtained as sum of common chronic painful conditions such as 
back/neck pain, headache/migraine, arthritis/joint pain, and neuropathic pain/other chronic pain conditions.                                                                                                                   
c Physical chronic conditions examined included conditions other than CNPC conditions such as asthma, 
coronary artery disease, cardiac arrhythmias, congestive heart failure, chronic kidney disease, chronic 
obstructive pulmonary disease, diabetes, hypertension, hyperlipidemia, osteoporosis, and stroke. 
 
 
 
 
 
 
 
 
